US20120006704A1 - Pharmaceutical composition container - Google Patents
Pharmaceutical composition container Download PDFInfo
- Publication number
- US20120006704A1 US20120006704A1 US13/257,426 US201013257426A US2012006704A1 US 20120006704 A1 US20120006704 A1 US 20120006704A1 US 201013257426 A US201013257426 A US 201013257426A US 2012006704 A1 US2012006704 A1 US 2012006704A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- aforementioned
- container
- chamber
- swallowing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 456
- 239000000126 substance Substances 0.000 claims abstract description 164
- 239000000155 melt Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000003749 cleanliness Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 description 61
- 238000000034 method Methods 0.000 description 27
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- 239000000463 material Substances 0.000 description 20
- 238000003860 storage Methods 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000037406 food intake Effects 0.000 description 12
- 238000007789 sealing Methods 0.000 description 10
- 230000009747 swallowing Effects 0.000 description 9
- 235000019658 bitter taste Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 239000000057 synthetic resin Substances 0.000 description 4
- 229920003002 synthetic resin Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000000805 composite resin Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/202—Separating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/202—Separating means
- A61J1/2024—Separating means having peelable seals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
- B65D81/3261—Flexible containers having several compartments
- B65D81/3266—Flexible containers having several compartments separated by a common rupturable seal, a clip or other removable fastening device
Definitions
- This invention relates to a pharmaceutical composition container; more specifically, to a pharmaceutical composition container so configured as to allow the improvement of cleanliness when the pharmaceutical composition is swallowed.
- Patent document 1 discloses a multi-chamber container.
- This multi-chamber container is so partitioned into a plurality of spaces as to enable the spaces to be interconnected with each other.
- the spaces are sealed in such a state that they can be interconnected with each other by means of force applied from the outside.
- a granular agent is stored in a tightly sealed state in any of the spaces.
- a thick fluid substance is stored in a tightly sealed state in one or more other spaces. After interconnecting the spaces with each other and gathering and mixing the granular agent with the thick fluid substance, it is possible to take out the mixture from a take-out port provided on any of the spaces.
- patent document 1 bears the problem that it is highly probable that bacteria or other matter having an adverse effect on the patient enter the body of the patient when the patient takes the granular agent.
- the technical issue addressed by this invention is intended to solve the abovementioned problem, and the purpose of the invention is to provide a pharmaceutical composition container that allows the improvement of cleanliness when the pharmaceutical composition is swallowed.
- the pharmaceutical composition container ( 10 ) is equipped with at least three spaces ( 30 , 32 , 34 , 36 , 38 ) inside a container body ( 20 ).
- the pharmaceutical composition container ( 10 ) is further equipped with a cover ( 22 ).
- the portions ( 140 , 142 , 144 , 146 ) between two adjoining spaces are sealed.
- the portions ( 140 , 142 , 144 , 146 ) between two adjoining spaces open when force is applied from the outside of the pharmaceutical composition container ( 10 ).
- At least one of the spaces is a apertured space ( 38 ), which comprises an aperture ( 60 ).
- a swallowing-aid substance ( 40 ) is stored in a swallowing-aid substance chamber ( 30 ), which is at least one of the spaces.
- Pharmaceutical compositions ( 80 , 82 ) are stored in pharmaceutical composition chambers ( 34 , 36 ), each of which is at least one of the spaces.
- the portion forming the apertured space ( 38 ) is covered by a cover ( 22 ).
- the portions ( 140 , 142 , 144 , 146 ) between two adjoining spaces are sealed.
- the portions ( 140 , 142 , 144 , 146 ) open.
- the swallowing-aid substance ( 40 ) can be guided from the swallowing-aid substance chamber ( 30 ) to the pharmaceutical composition chambers ( 34 , 36 ).
- the pharmaceutical compositions ( 80 , 82 ) are mixed with the swallowing-aid substance ( 40 ).
- the abovementioned cover ( 22 ) be integrated with the container body ( 20 ).
- the abovementioned at least three spaces ( 30 , 32 , 34 , 36 , 38 ) and the cover ( 22 ) be arranged so as to form one row.
- the apertured space ( 38 ) is disposed on one end of the row.
- the cover ( 22 ) is disposed on the other end of the row.
- the container body ( 20 ) and the cover ( 22 ) can be folded over, and folding over the container body ( 20 ) and the cover ( 22 ) brings the aperture ( 60 ) and the cover ( 22 ) into a state of facing each other.
- the encapsulating items ( 42 , 44 ) be stored in the abovementioned pharmaceutical composition chambers ( 34 , 36 ). In this case, at least the surface of the encapsulating items ( 42 , 44 ) melts in the ingredients of the swallowing-aid substance ( 40 ).
- the encapsulating items ( 42 , 44 ) contain the pharmaceutical compositions ( 80 , 82 ).
- the swallowing-aid substance ( 40 ) When the swallowing-aid substance ( 40 ) is guided into the pharmaceutical composition chambers ( 34 , 36 ), at least the surface of the encapsulating items ( 42 , 44 ) melts in the swallowing-aid substance ( 40 ). Thereby, when holding the aperture ( 60 ) against the mouth of a person with swallowing difficulties and pushing out the swallowing-aid substance ( 40 ) and the encapsulating items ( 42 , 44 ) from this aperture ( 60 ), the encapsulating items ( 42 , 44 ) will enter the mouth of the person with swallowing difficulties while being enclosed in swallowing-aid substance ( 40 ). At this time, the surface of encapsulating items ( 42 , 44 ) has melted.
- the encapsulating items ( 42 , 44 ) can easily be swallowed even by a person with swallowing difficulties because the encapsulating items ( 42 , 44 ) are enclosed in the swallowing-aid substance ( 40 ) and the surface of encapsulating items ( 42 , 44 ) has melted.
- This means that the pharmaceutical compositions ( 80 , 82 ) are also swallowed with the swallowing of the encapsulating items ( 42 , 44 ).
- the pharmaceutical compositions ( 80 , 82 ) in the encapsulating items ( 42 , 44 ) do not scatter until the encapsulating items ( 42 , 44 ) have sufficiently melted.
- the pharmaceutical composition container ( 351 ) is equipped with a plurality of spaces ( 370 , 372 , 374 ) inside the container body.
- the container body is provided with a predetermined aperture part ( 394 ), wherein an aperture is to be formed.
- the aperture is opened when force is applied to the pharmaceutical composition container ( 351 ) from the outside, thereby interconnecting the outside of the pharmaceutical composition container ( 351 ) with the space.
- the portions ( 390 , 392 ) between two adjoining spaces of spaces ( 370 , 372 , 374 ) are sealed.
- a swallowing-aid substance ( 40 ) is stored in a swallowing-aid substance chamber ( 370 ), which is at least one of the spaces.
- a pharmaceutical composition is stored in pharmaceutical composition chambers ( 372 , 374 ), which are at least one of the spaces.
- the container body can be folded over.
- the pharmaceutical composition container ( 351 ) is further equipped with a cover ( 378 ).
- the cover ( 378 ) is disposed so as to adjoin the container body.
- the cover ( 378 ) is integrated with the container body.
- the cover ( 378 ) allows pulling out or inserting the portion ( 354 ) of the container body which is provided with the predetermined aperture part ( 394 ).
- the portion ( 354 ) which is provided with the predetermined aperture part ( 394 ) is covered by the cover ( 378 ).
- FIG. 1 is a partial cross section of the pharmaceutical composition container of the embodiment 1 of this invention.
- FIG. 2 is a cross section of the pharmaceutical composition container of the embodiment 1 of this invention.
- FIG. 3 is an enlarged cross section of the pharmaceutical composition container of the embodiment 1 of this invention.
- FIG. 4 shows the production procedure for the pharmaceutical composition container of the embodiment 1 of this invention.
- FIG. 5 shows the usage method of the pharmaceutical composition container of the embodiment 1 of this invention.
- FIG. 6 is a partial cross section of the pharmaceutical composition container of the embodiment 2 of this invention.
- FIG. 7 is a partial cross section of the pharmaceutical composition container of the embodiment 3 of this invention.
- FIG. 8 is a partial cross section of the pharmaceutical composition container of the embodiment 4 of this invention.
- FIG. 9 is a partial cross section of the pharmaceutical composition container of the embodiment 5 of this invention.
- FIG. 10 is a partial cross section of the pharmaceutical composition container of the embodiment 6 of this invention.
- FIG. 11 is an external view of the pharmaceutical composition container of the embodiment 6 of this invention.
- FIG. 12 shows a state of the embodiment 6 of this invention wherein the cover insert portion is inserted into the cover and the base is on the outside of the cover.
- FIG. 13 is a rear view of the state in the embodiment 6 of this invention wherein the cover insert portion is inserted into the cover.
- FIG. 14 is a partial cross section of the pharmaceutical composition container of the embodiment 7 of this invention.
- FIG. 15 shows the state of the embodiment 7 of this invention wherein the pharmaceutical composition container is folded.
- FIG. 16 shows the state of the embodiment 7 of this invention after one end of the pharmaceutical composition container was inserted into the cover.
- FIG. 17 is a partial cross section of the pharmaceutical composition container of the embodiment 8 of this invention.
- FIG. 18 is a partial cross section showing one end of the pharmaceutical composition container of the embodiment 8 of this invention during the production thereof.
- FIG. 19 is a perspective view showing one end of the pharmaceutical composition container of the embodiment 8 of this invention during the production thereof.
- FIG. 20 is a partial cross section of the pharmaceutical composition container of the embodiment 9 of this invention.
- FIG. 21 is an external view of the state of the embodiment 9 of this invention wherein one end of the pharmaceutical composition container is inserted into the cover.
- the configuration of the pharmaceutical composition container 10 of this embodiment will be explained while referring to FIG. 1 .
- the pharmaceutical composition container 10 of this embodiment is equipped with a container body 20 and a cover 22 , which is integrated with the container body 20 .
- the container body 20 and the cover 22 of this embodiment are formed by adhering two laminated members 50 to each other.
- the laminated member 50 will be explained later.
- the container body 20 is equipped with a swallowing-aid substance chamber 30 , an intermediate chamber 32 , a first pharmaceutical composition chamber 34 , a second pharmaceutical composition chamber 36 and an apertured space 38 .
- the swallowing-aid substance chamber 30 , the intermediate chamber 32 , the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 are so formed as to maintain air tightness with respect to the external space around the pharmaceutical composition container 10 .
- FIG. 2 is a cross section of the pharmaceutical composition container 10 of this embodiment. In the mode shown in FIG. 2 , the cover 22 can cover the outside of the portion of the container body 20 which forms the apertured space 38 . This is possible because the laminated member 50 of this embodiment can be folded over.
- a swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 30 .
- the swallowing-aid substance 40 in this embodiment is a sterilized jelly containing water.
- the water content of the jelly in this embodiment is established in such a manner that the following requirement is fulfilled. The requirement is that it must be possible to provide at least two minutes from the time when the swallowing-aid substance 40 covers the surface of the first encapsulating item 42 and the second encapsulating item 44 , which will be explained later, until the time when the first encapsulating item 42 and the second encapsulating item 44 completely melt.
- a first encapsulating item 42 is stored inside the first pharmaceutical composition chamber 34 .
- a granular drug or another first pharmaceutical composition 80 is encapsulated inside the first encapsulating item 42 .
- the material of the first encapsulating item 42 in this embodiment is a wafer which is made of starch and has a thickness of 15 ⁇ m.
- a second encapsulating item 44 is stored inside the second pharmaceutical composition chamber 36 .
- a second pharmaceutical composition 82 is encapsulated inside the second encapsulating item 44 .
- the second pharmaceutical composition 82 is a substance of a type that is different to that of the granular first pharmaceutical composition 80 .
- the material of the second encapsulating item 44 in this embodiment is a wafer which is made of starch and has a thickness of 10 ⁇ m.
- the openings of the first encapsulating item 42 and the second encapsulating item 44 are sealed by the twisting of the portions corresponding to the inlets for the first pharmaceutical composition 80 and the second pharmaceutical composition 82 .
- That a wafer is used as the material for the first encapsulating item 42 and the second encapsulating item 44 is because the first encapsulating item 42 and the second encapsulating item 44 are required to have the following function.
- the function is that, when the swallowing-aid substance 40 covers the surface of the first encapsulating item 42 or the second encapsulating item 44 , the surface thereof must start to melt, and after the first encapsulating item 42 and the second encapsulating item 44 are swallowed, the first encapsulating item 42 and the second encapsulating item 44 must completely melt.
- That the wafer used for the first encapsulating item 42 is thicker than the wafer used for the second encapsulating item 44 is because the time from when the wafer begins to be covered by the swallowing-aid substance 40 until the wafer completely melts is required to be set to a longer time for the first encapsulating item 42 than for the second encapsulating item 44 .
- the reason for this requirement is that the first encapsulating item 42 is covered by the swallowing-aid substance 40 earlier than the second encapsulating item 44 .
- That a wafer of a thickness of 10 ⁇ m is used as the material for the second encapsulating item 44 is in order to provide at least two minutes of time from when the second encapsulating item 44 is covered by the swallowing-aid substance 40 until the second encapsulating item 44 completely melts.
- the thickness of the wafer should be selected as appropriate depending on the material properties thereof.
- a gas for example, nitrogen gas which does not have any effect on the first pharmaceutical composition 80 , the second pharmaceutical composition 82 and the swallowing-aid substance 40 , is filled into the first swallowing-aid substance chamber 30 , the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 .
- the intermediate chamber 32 and the apertured space 38 of this embodiment are empty chambers until the first weak seal 140 to fourth weak seal 146 , which will be explained later, are broken.
- An empty chamber is a space in which nothing is stored, or in which a gas is stored that does not have any effect on the first pharmaceutical composition 80 , the second pharmaceutical composition 82 or the swallowing-aid substance 40 .
- the apertured space 38 comprises an aperture 60 .
- the aperture 60 interconnects the outside of the swallowing-aid substance chamber 30 , the intermediate chamber 32 , the first pharmaceutical composition chamber 34 , the second pharmaceutical composition chamber 36 and the apertured space 38 with the inside thereof.
- the aperture 60 interconnects the inside of those of the swallowing-aid substance chamber 30 , the intermediate chamber 32 , the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 which are interconnected with the apertured space 38 , with the outside of those spaces.
- the portion between the swallowing-aid substance chamber 30 and the intermediate chamber 32 is partitioned by a first weak seal 140 .
- the portion between the intermediate chamber 32 and the first pharmaceutical composition chamber 34 is partitioned by a second weak seal 142 .
- the portion between the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 is partitioned by a third weak seal 144 .
- the portion between the second pharmaceutical composition chamber 36 and the apertured space 38 is partitioned by a fourth weak seal 146 .
- the first weak seal 140 , the second weak seal 142 , the third weak seal 144 and the fourth weak seal 146 (these are referred to as “first weak seal 140 to fourth weak seal 146 ”) are disposed in the portions between two adjoining spaces of the spaces provided in the container body 20 .
- the strength of the first weak seal 140 to fourth weak seal 146 is weaker than the strength of the bottom strong seal 160 and the side strong seal 162 .
- the bottom strong seal 160 is the portion on the boundary between the container body 20 and the cover 22 where the surfaces of the laminated members 50 are adhered to each other.
- the side strong seal 162 is the portion where the surfaces of the laminated members 50 are adhered to each other excluding the first weak seal 140 to fourth weak seal 146 and the bottom strong seal 160 .
- the strength of the first weak seal 140 to fourth weak seal 146 is such that the first weak seal 140 to fourth weak seal 146 can be broken by the pressure of the swallowing-aid substance 40 (this pressure being caused by the application of force by an adult person from the outside of the swallowing-aid substance chamber 30 ).
- the specific method for breaking the portion between the swallowing-aid substance chamber 30 and the intermediate chamber 32 , the portion between the intermediate chamber 32 and the first pharmaceutical composition chamber 34 , the portion between the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 and the portion between the second pharmaceutical composition chamber 36 and the apertured space 38 is not limited to breaking by means of pressure from the swallowing-aid substance 40 .
- the first weak seal 140 to fourth weak seal 146 may also be ripped apart by holding one of the two laminated members 50 in each hand and pulling the laminated members apart.
- FIG. 3 is an enlarged cross section of the pharmaceutical composition container 10 of this embodiment.
- the configuration of the laminated member 50 and the configuration of the first weak seal 140 to fourth weak seal 146 will be explained while referring to FIGS. 1 and 3 .
- the laminated member 50 of this embodiment comprises an outer skin member 100 , an intermediate member 102 and a sealing member 104 (note that this three-layered structure of the laminated member 50 is not depicted (is omitted) in FIG. 2 ).
- the sealing members 104 and 104 of two laminated members 50 are fusion-bonded to each other. This fusion-bonded portion is broken prior to the outer skin member 100 and the intermediate member 102 by force applied from the outside of the pharmaceutical composition container 10 .
- the fusing point of the sealing member 104 is low. For this reason, the sealing member 104 melts before the outer skin member 100 and the intermediate member 102 melt when heat is applied to the laminated member 50 from the outside of the outer skin member 100 . Since the sealing member 104 melts before the outer skin member 100 and the intermediate member 102 melt, it is possible to fusion-bond only the sealing member 104 . These fusion-bonded portions are the first weak seal 104 to fourth weak seal 146 . FIG. 3 shows only the fourth weak seal 146 .
- the material of those portions of the sealing member 104 that correspond to the first weak seal 140 to fourth weak seal 146 is different from the material of those portions of the sealing member 104 that correspond to the bottom strong seal 160 and the side strong seal 162 (however, the material of the outer skin member 100 and the material of the intermediate member 102 are the same between the portion corresponding to the first weak seal 140 to fourth weak seal 146 and the portion corresponding to the bottom strong seal 160 and the side strong seal 162 ). Since the materials are different, it is possible to make the strength of the first weak seal 140 to fourth weak seal 146 weaker than the strength of the bottom strong seal 160 and the side strong seal 162 .
- the material of the outer skin member 100 is polyethylene terephthalate.
- the material of the intermediate member 102 is nylon.
- the material of those portions of the sealing member 104 which correspond to the first weak seal 140 to fourth weak seal 146 is polyethylene.
- FIG. 4 shows the production procedure for the pharmaceutical composition container 10 of this embodiment.
- the production procedure for the pharmaceutical composition container 10 will be explained while referring to FIG. 4 .
- the first step the two laminated members 50 and 50 are superposed on each other and the portion corresponding to the side of the pharmaceutical composition container 10 is heated. Thereby, as is shown in FIG. 4 (A), the side strong seal 162 is formed.
- the second step the periphery of the intermediate chamber 32 on the laminated member 50 is heated. Thereby, as is shown in FIG. 4 (B), the first weak seal 140 and the second weak seal 142 are formed.
- the first encapsulating item 42 is inserted between the two laminated members 50 and 50 , as is shown in FIG. 4 (C).
- the periphery of the portion between the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 on the laminated member 50 is heated. Thereby, as is shown in FIG. 4 (D), the third weak seal 144 is formed.
- the second encapsulating item 44 is inserted between the two laminated members 50 and 50 , as is shown in FIG. 4 (E).
- the periphery of the portion between the second pharmaceutical composition chamber 36 and the apertured space 38 on the laminated member 50 is heated. Thereby, as is shown in FIG. 4 (F), the fourth weak seal 146 is formed.
- the swallowing-aid substance 40 is filled between the two laminated members 50 and 50 .
- the portion of the first weak seal 140 on the container body 20 is folded over, and the swallowing-aid substance chamber 30 is oriented upwards.
- a nozzle which is not shown in the drawing, is inserted into the swallowing-aid substance chamber 30 to fill in the swallowing-aid substance 40 .
- the boundary portion between the container body 20 and the cover 22 is heated. Thereby, as is shown in FIG. 4 (G), the bottom strong seal 160 is formed.
- the boundary portion between the container body 20 and the cover 22 is folded over as shown in FIG. 4 (H), and then the portion of the container body 20 which forms the apertured space 38 is inserted between the cover 22 .
- the pharmaceutical composition container 10 which is completed through these steps is packed into a carton box which is not shown in the drawings, and distributed.
- FIG. 5 shows the usage method of the pharmaceutical composition container 10 of this embodiment.
- the procedure for taking the first pharmaceutical composition 80 and the second pharmaceutical composition 82 out of the pharmaceutical composition container 10 and ingesting the first pharmaceutical composition 80 and the second pharmaceutical composition 82 will be explained while referring to FIG. 5 .
- the caretaker etc. pulls the tip portion of the container body 20 out of the cover 22 , thereby bringing the pharmaceutical composition container 10 , which had been in the state shown in FIG. 4 (H), into the state shown in FIG. 1 or FIG. 4 (G).
- the caretaker etc. presses the swallowing-aid substance chamber 30 from the outside of the pharmaceutical composition container 10 to break the first weak seal 140 by means of the pressure from inside the swallowing-aid substance chamber 30 .
- the swallowing-aid substance 40 is pushed out into the intermediate chamber 32 .
- the swallowing-aid substance 40 that was pushed out fills the inside of the intermediate chamber 32 .
- the second weak seal 142 is broken by the pressure of the swallowing-aid substance 40 inside the intermediate chamber 32 .
- the caretaker etc. folds the cover 22 towards the container body 20 .
- the second weak seal 142 is broken, the swallowing-aid substance 40 is pushed out into the first pharmaceutical composition chamber 34 .
- the swallowing-aid substance 40 that was pushed out fills the inside of the first pharmaceutical composition chamber 34 . From this time, the surface of the first encapsulating item 42 starts to melt in the swallowing-aid substance 40 .
- the caretaker etc. lets the patient 200 put the pharmaceutical composition container 10 into the mouth.
- the patient 200 folds the cover 22 , which was folded back towards the container body 20 , further towards the container 20 and squeezes the container body 20 and the cover 22 .
- pressure is applied to the swallowing-aid substance 40 .
- the third weak seal 144 breaks.
- the swallowing-aid substance 40 is pushed out together with the first encapsulating item 42 into the second pharmaceutical composition chamber 36 .
- the swallowing-aid substance 40 that was pushed out fills the inside of the second pharmaceutical composition chamber 36 . From this time, the surface of the second encapsulating item 44 also starts to melt in the swallowing-aid substance 40 .
- the patient 200 folds back the container body 20 and the cover 22 from the swallowing-aid substance chamber 30 further towards the second pharmaceutical composition chamber 36 and further squeezes same. Thereby, pressure is applied to the swallowing-aid substance 40 .
- the fourth weak seal 146 breaks. When the fourth weak seal 146 is broken, the swallowing-aid substance 40 , the first encapsulating item 42 and the second encapsulating item 44 are pushed out into the apertured space 38 .
- the swallowing-aid substance 40 , the first encapsulating item 42 and the second encapsulating item 44 are swallowed via the apertured space 38 and the mouth of the patient 200 .
- the surfaces of the first encapsulating item 42 and the second encapsulating item 44 have melted in the ingredients of the swallowing-aid substance 40 ; therefore the surfaces of the first encapsulating item 42 and the second encapsulating item 44 are now slippery. Because the surfaces of the first encapsulating item 42 and the second encapsulating item 44 are slippery, the first encapsulating item 42 and the second encapsulating item 44 are swallowed smoothly.
- the pharmaceutical composition container 10 of this embodiment produces the following eight effects.
- the first effect is that it is possible to easily swallow the first pharmaceutical composition 80 and the second pharmaceutical composition 82 .
- the second effect is that, if the first pharmaceutical composition 80 and the second pharmaceutical composition 82 have a bitter taste, that bitter taste is suppressed.
- the third effect is that it is possible to suppress the scattering of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 in the mouth.
- the fourth effect is that concerns regarding the stability of the first pharmaceutical composition and the second pharmaceutical composition 82 become unnecessary.
- the fifth effect is that it is possible to let patients with swallowing difficulties ingest solids of various types.
- the sixth effect is that it is possible to improve the cleanliness during the ingestion of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 .
- the seventh effect is that it is possible to smoothly push out the first encapsulating item 42 and the second encapsulating item 44 .
- the eighth effect is that it is possible to reduce the residual quantity of the pharmaceutical compositions 80 and 82 inside the pharmaceutical composition container 10 (in this embodiment, it is possible to reduce the residual quantity close to zero).
- the first effect will now be explained in detail.
- the first encapsulating item 42 and the second encapsulating item 44 enter the mouth of the patient 200 while being enclosed in the swallowing-aid substance 40 .
- the surfaces of the first encapsulating item 42 and the second encapsulating item 44 have melted.
- the first encapsulating item 42 and the second encapsulating item 44 can easily be swallowed even by a person with swallowing difficulties because the first encapsulating item 42 and the second encapsulating item 44 are enclosed in the swallowing-aid substance 40 and the surfaces thereof have melted.
- the pharmaceutical composition 80 is inside the first encapsulating item 42 and the second encapsulating item 44 , the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are also swallowed when the first encapsulating item 42 and the second encapsulating item 44 are swallowed. Thereby it is possible to easily swallow the first pharmaceutical composition 80 and the second pharmaceutical composition 82 .
- the first encapsulating item 42 and the second encapsulating item 44 enter the mouth of the patient 200 while being enclosed in the swallowing-aid substance 40 .
- the first pharmaceutical composition 80 and the second pharmaceutical composition 82 which are the content of the first encapsulating item 42 and the second encapsulating item 44 , are doubly enclosed by the swallowing-aid substance 40 and by the first encapsulating item 42 and second encapsulating item 44 .
- the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are drugs, the probability that the tongue of the patient 200 senses the bitterness thereof is low because the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are doubly enclosed. As a result, the bitter taste of the drugs is suppressed.
- the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are doubly enclosed by the swallowing-aid substance 40 and by the first encapsulating item 42 and the second encapsulating item 44 .
- the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are chemical substances. When chemical substances come into contact with each other, chemical reactions occur in many cases. Due to the occurrence of chemical reactions, the effect of the pharmaceutical composition as a drug is lost. For this reason, it is not possible to preserve a plurality of pharmaceutical compositions in a mixed state in many cases. If the pharmaceutical compositions are to be preserved in a mixed state, it is necessary to research in advance whether the chemical substances lose their effects.
- the pharmaceutical composition container 10 of this embodiment is equipped with a plurality of spaces. Storing one type of pharmaceutical composition in each of those spaces is substantially identical with separately preserving a plurality of pharmaceutical compositions.
- the swallowing-aid substance 40 As the swallowing-aid substance 40 , the first encapsulating item 42 and the second encapsulating item 44 are swallowed after the swallowing-aid substance 40 is sequentially guided to the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 , the activity of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 per se will not have a significant effect on the difficulty or easiness of swallowing any more. Thereby it is possible to let patients with swallowing difficulties ingest solids of various types.
- the portion of the container body that forms the apertured space 38 is covered by the cover 22 .
- the frequency at which bacteria etc. adhere is reduced particularly in comparison with the case where the portion of the container body 20 which comes into contact with the mouth is broken to form the aperture.
- the swallowing-aid substance 40 , the first encapsulating item 42 and the second encapsulating item 44 can be swallowed upon breaking the first weak seal 140 to fourth weak seal 146 ; therefore it is not necessary to touch, with a tool or hand, the portion of the container body 20 which comes into contact with the mouth and thus the probability that bacteria or viruses adhere thereto is reduced. As a result, it is possible to improve the cleanliness during the ingestion of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 .
- the seventh effect will now be explained in detail.
- the end of the first pharmaceutical composition chamber 34 on the side of the second pharmaceutical composition chamber 36 becomes narrower towards the second pharmaceutical composition chamber 36 , and the first encapsulating item 42 is stored in the first pharmaceutical composition chamber 34 ; therefore it is possible to smoothly push out the first encapsulating item 42 by means of the swallowing-aid substance 40 .
- the end of the second pharmaceutical composition chamber 36 on the side of the apertured space 38 becomes narrower towards the apertured space 38 , and the second encapsulating item 44 is stored in the second pharmaceutical composition chamber 36 ; therefore this second encapsulating item 44 is also pushed out smoothly in the same way.
- the first encapsulating item 42 and the second encapsulating item 44 are pushed out of the aperture 60 , the first pharmaceutical composition 80 and the second pharmaceutical composition 82 therein are pushed out at the same time.
- the first encapsulating item 42 and the second encapsulating item 44 of this embodiment are tightly sealed.
- the probability that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 leak from the first encapsulating item 42 and the second encapsulating item 44 is extremely low. Since this probability is extremely low, it is possible to reduce the residual quantity of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 remaining inside the pharmaceutical composition container 10 (actually, it is possible to reduce the residual quantity close to zero).
- FIG. 6 is a partial cross section of the pharmaceutical composition container 210 of this embodiment.
- the configuration of the pharmaceutical composition container 210 of this embodiment will be explained while referring to FIG. 6 .
- the pharmaceutical composition container 210 of this embodiment is equipped with a container body 220 and a cover 222 .
- the container body 220 is formed by one laminated member 50 that is folded and has the outer periphery adhered together.
- the cover 222 is formed from a laminated member 50 same as the container body 220 .
- the cover 222 is integrated with the container body 220 .
- the hatched portion at the left end of the pharmaceutical composition container 210 shows a cross section of the laminated member 50 .
- the container body 220 comprises a swallowing-aid substance chamber 230 , a pharmaceutical composition chamber 232 and an apertured space 234 .
- the swallowing-aid substance chamber 230 and the pharmaceutical composition chamber 232 are so formed as to maintain air tightness with respect to the external space around the pharmaceutical composition container 210 .
- a swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 230 .
- a first encapsulating item 42 is stored inside the pharmaceutical composition chamber 232 .
- a first pharmaceutical composition 80 is encapsulated inside the first encapsulating item 42 .
- the apertured space 234 is an empty chamber until the first weak seal 240 and the second weak seal 242 , which will be explained later, are broken.
- a gas which does not have any effect on the first pharmaceutical composition 80 or the swallowing-aid substance 40 is filled into the swallowing-aid substance chamber 230 and the pharmaceutical composition chamber 232 .
- the portion between the swallowing-aid substance chamber 230 and the pharmaceutical composition chamber 232 is partitioned by a first weak seal 240 .
- the portion between the pharmaceutical composition chamber 232 and the apertured space 234 is partitioned by a second weak seal 242 .
- the first weak seal 240 and the second weak seal 242 are disposed in the portions corresponding to the portions between two adjoining spaces of the spaces formed by the container body 220 .
- the strength of the first weak seal 240 and the second weak seal 242 is weaker than the strength of the bottom strong seal 260 and the side strong seal 262 .
- the bottom strong seal 260 is the portion on the boundary between the container body 220 and the cover 222 where the surfaces of the laminated members 50 are adhered to each other.
- the side strong seal 262 is the portion where the surfaces of the laminated member 50 are adhered to each other excluding the first weak seal 240 , the second weak seal 242 and the bottom strong seal 260 .
- the strength of the first weak seal 240 and the second weak seal 242 is such that the first weak seal 240 and the second weak seal 242 can be broken by the pressure of the swallowing-aid substance 40 , same as in the embodiment 1.
- the specific method for breaking the first weak seal 240 and the second weak seal 242 is not limited to breaking by means of the pressure from the swallowing-aid substance 40 .
- the configuration of the first weak seal 240 and the second weak seal 242 is the same as the configuration of the first weak seal 140 to fourth weak seal 146 of the embodiment 1. Further, the configuration of the bottom strong seal 260 and the side strong seal 262 is the same as that of the bottom strong seal 160 and the side strong seal 162 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here.
- FIG. 6 shows a state where only one of those corners is folded over. Those two corners are folded over in order to facilitate the insertion of the portion corresponding to the tip of the apertured space 234 into the cover 222 in the same way as in the embodiment 1. Accordingly, if there is no particular problem, only one of those two corners may be folded over.
- the production method and usage method of the pharmaceutical composition container 210 of this embodiment is the same as the production method and usage method of the pharmaceutical composition container 10 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here.
- the pharmaceutical composition container 210 of this embodiment produces the following six effects.
- the first effect is that it is possible to easily swallow the first pharmaceutical composition 80 .
- the second effect is that, if the first pharmaceutical composition 80 has a bitter taste, that bitter taste is suppressed.
- the third effect is that it is possible to suppress the scattering of the first pharmaceutical composition 80 in the mouth.
- the fourth effect is that it is possible to let patients with swallowing difficulties ingest solids of various types.
- the fifth effect is that it is possible to improve the cleanliness during the ingestion of the first pharmaceutical composition 80 . The reasons why those effects are produced are the same as in the case of the embodiment 1, and therefore a detailed explanation thereof will not be repeated here.
- the sixth effect is that it is possible to reduce the residual quantity of the pharmaceutical composition 80 inside the pharmaceutical composition container 210 (in this embodiment, it is possible to reduce the residual quantity close to zero).
- FIG. 7 is a partial cross section of the pharmaceutical composition container 310 of this embodiment.
- the configuration of the pharmaceutical composition container 310 of this embodiment will be explained while referring to FIG. 7 .
- the pharmaceutical composition container 310 of this embodiment is equipped with a container body 320 and a cover 322 .
- the container body 220 is formed by melt-bonding the outer edge of two laminated members 50 .
- the cover 222 is separate from the container body 220 .
- the sheet forming the cover 222 in this embodiment is formed of a known resin.
- the container body 320 comprises a bag storage chamber 330 , a first pharmaceutical composition chamber 334 , a second pharmaceutical composition chamber 336 and an apertured space 338 .
- the bag storage chamber 330 , the first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 are so formed as to maintain air tightness with respect to the external space around the container body 320 .
- An aid-substance storage bag 340 is stored inside the bag storage chamber 330 .
- the aid-substance storage bag 340 is fixed inside the bag storage chamber 330 by means of the circumferential strong seal 462 , which will be explained later.
- a swallowing-aid substance 40 is stored inside the aid-substance storage bag 340 .
- the strength of the end facing the first weak seal 440 which will be explained later, has the same structure as that of the first weak seal 140 to fourth weak seal 146 of the embodiment 1. Accordingly, this portion can be broken by the pressure of the swallowing-aid substance 40 .
- the swallowing-aid substance 40 is sterilized together with the aid-substance storage bag 340 and then sandwiched in the container body 320 . After that, the circumferential strong seal 462 is formed, whereby the aid-substance storage bag 340 is adhered inside the circumferential strong seal 462 .
- a first encapsulating item 42 is stored inside the first pharmaceutical composition chamber 334 .
- a first pharmaceutical composition 80 is encapsulated inside the first encapsulating item 42 .
- a powder drug 344 is stored inside the second pharmaceutical composition chamber 336 .
- the apertured space 338 in this embodiment is an empty chamber until the first weak seal 440 to third weak seal 444 are broken.
- first weak seal 440 The portion between the bag storage chamber 330 and the first pharmaceutical composition chamber 334 is partitioned by a first weak seal 440 .
- the portion between the first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 is partitioned by a second weak seal 442 .
- the portion between the second pharmaceutical composition chamber 336 and the apertured space 338 is partitioned by a third weak seal 444 .
- the first weak seal 440 , the second weak seal 442 and the third weak seal 444 (these are referred to as “first weak seal 440 to third weak seal 444 ”) are disposed in the portions between two adjoining spaces of the spaces formed by the container body 320 .
- the strength of the first weak seal 440 to third weak seal 444 is weaker than the strength of the circumferential strong seal 462 .
- the circumferential strong seal 462 is the portion where the edge of the container body 320 is adhered.
- the strength of the first weak seal 440 to third weak seal 444 is such that the first weak seal 440 to third weak seal 444 can be broken by the pressure of the swallowing-aid substance 40 , same as in the embodiments 1 and 2.
- the specific method for breaking the first weak seal 440 to third weak seal 444 is not limited to breaking by means of the pressure from the swallowing-aid substance 40 .
- the configuration of the first weak seal 440 to third weak seal 444 is the same as the configuration of the first weak seal 140 to fourth weak seal 146 of the embodiment 1. Further, the configuration of the circumferential strong seal 462 is the same as that of the side strong seal 162 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here.
- the production procedure for the pharmaceutical composition container 310 of this embodiment will now be explained.
- the first step two sheets of a laminated member 50 are superposed on each other and the outer edge thereof is heated. However, no heat is applied to the portion where the aid-substance storage bag 340 is to be sandwiched.
- the periphery of the first weak seal 440 on the laminated member 50 is heated. Thereby, the first weak seal 440 is formed.
- the first encapsulating item 42 is inserted between the laminated members 50 .
- the periphery of the portion between the first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 on the laminated member 50 is heated. Thereby the second weak seal 442 is formed.
- the powder drug 344 is filled between the laminated member 50 .
- the periphery of the portion between the second pharmaceutical composition chamber 336 and the apertured space 338 on the laminated member 50 is heated. Thereby the third weak seal 444 is formed.
- the aid-substance storage bag 340 is inserted between the laminated member 50 .
- the portion of the first weak seal 440 on the container body 320 is folded over, and the bag storage chamber 330 is oriented upwards.
- the aperture on the bag storage chamber 330 is opened widely and the aid-substance storage bag 340 is inserted thereinto.
- the portion on the outer edge of the container body 320 where the aid-substance storage bag 340 is sandwiched is heated.
- the cover 322 is placed over the outer side of the portion of the container body 320 which forms the apertured space 338 .
- the pharmaceutical composition container 310 which is completed through these steps is packed into a carton box which is not shown in the drawings, and distributed.
- the usage method of the pharmaceutical composition container 310 of this embodiment is the same as the usage method of the pharmaceutical composition container 10 of the embodiment 1 except for the fact that first the cover 322 is removed from the portion of the container body 320 which forms the apertured space 338 . Accordingly, a detailed explanation thereof will not be repeated here.
- the pharmaceutical composition container 310 of this embodiment produces the following five effects.
- the first effect is that it is possible to easily swallow a granular drug or another pharmaceutical composition 80 .
- the second effect is that, if the first pharmaceutical composition 80 has a bitter taste, that bitter taste is suppressed.
- the third effect is that concerns regarding the stability of the drug become unnecessary.
- the fourth effect is that it is possible to improve the cleanliness during the ingestion of the first pharmaceutical composition 80 and the powder drug 344 .
- the fifth effect is that it is possible to reduce the residual quantity of the pharmaceutical compositions 80 and 82 inside the pharmaceutical composition container 310 (in this embodiment, it is possible to reduce the residual quantity close to zero). The reasons why those effects are produced are the same as in the case of the embodiment 1, and therefore a detailed explanation thereof will not be repeated here.
- FIG. 8 is a partial cross section of the pharmaceutical composition container 510 of this embodiment.
- the configuration of the pharmaceutical composition container 510 of this embodiment will be explained while referring to FIG. 8 .
- the pharmaceutical composition container 510 of this embodiment is equipped with a container body 520 and a cover 522 , which is integrated with the container body 520 .
- the container body 520 and the cover 522 of this embodiment are formed by double-folding one laminated member 50 and adhering the outer peripheries thereof.
- the hatched portion at the right end of the pharmaceutical composition container 510 shows a cross section of the laminated member 50 .
- the container body 520 is equipped with a swallowing-aid substance chamber 530 , an intermediate chamber 532 , a first pharmaceutical composition chamber 534 , a second pharmaceutical composition chamber 536 and an apertured space 538 .
- the swallowing-aid substance chamber 530 , the intermediate chamber 532 , the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 are so formed as to maintain air tightness with respect to the external space around the pharmaceutical composition container 510 .
- the cover 522 can cover the outside of the portion of the container body 520 which forms the apertured space 538 .
- a third pharmaceutical composition 84 is stored inside the first pharmaceutical composition chamber 534 .
- the third pharmaceutical composition 84 is a medicinal powder.
- a fourth pharmaceutical composition 86 is stored inside the second pharmaceutical composition chamber 536 .
- the fourth pharmaceutical composition 86 is a medicinal powder of a type that is different to that of the third pharmaceutical composition 84 .
- the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 may also store a granular drug or another substance.
- a gas which does not have any effect on the third pharmaceutical composition 84 , the fourth pharmaceutical composition 86 and the swallowing-aid substance 40 is filled into the swallowing-aid substance chamber 530 , the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 .
- the intermediate chamber 532 and the apertured space 538 are empty chambers until the first weak seal 640 to fourth weak seal 646 are broken.
- the apertured space 538 comprises an aperture.
- the portion between the swallowing-aid substance chamber 530 and the intermediate chamber 532 is partitioned by a first weak seal 640 .
- the portion between the intermediate chamber 532 and the first pharmaceutical composition chamber 534 is partitioned by a second weak seal 642 .
- the portion between the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 is partitioned by a third weak seal 644 .
- the portion between the second pharmaceutical composition chamber 536 and the apertured space 538 is partitioned by a fourth weak seal 646 .
- the strength of the first weak seal 640 to fourth weak seal 646 is weaker than the strength of the bottom strong seal 660 and the side strong seal 662 .
- the strength of the first weak seal 640 to fourth weak seal 646 is such that the first weak seal 640 to fourth weak seal 646 can be broken by the pressure of the swallowing-aid substance 40 (this pressure being caused by the application of force by an adult person from the outside of the swallowing-aid substance chamber 30 ).
- the specific method for breaking the portion between the swallowing-aid substance chamber 530 and the intermediate chamber 532 , the portion between the intermediate chamber 532 and the first pharmaceutical composition chamber 534 , the portion between the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 and the portion between the second pharmaceutical composition chamber 536 and the apertured space 538 is not limited to breaking by means of pressure from the swallowing-aid substance 40 .
- the usage method of the pharmaceutical composition container 510 of this embodiment is the same as the usage method of the pharmaceutical composition container 10 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here.
- the pharmaceutical composition container 510 of this embodiment produces the following four effects.
- the first effect is that it is possible to easily swallow a medicinal powder or another pharmaceutical composition.
- the second effect is that concerns regarding the stability of the drug become unnecessary.
- the third effect is that, because a step is provided on the portion of the side strong seal 662 that is adjacent to the third weak seal 644 , the tip of the pharmaceutical composition container 510 is prevented from entering the mouth of the patient 200 too far during the ingestion of a pharmaceutical composition using the pharmaceutical composition container 510 of this embodiment.
- the fourth effect is that it is possible to improve the cleanliness during the ingestion of the third pharmaceutical composition 84 and the fourth pharmaceutical composition 86 .
- FIG. 9 is a partial cross section of the pharmaceutical composition container 710 of this embodiment.
- the pharmaceutical composition container 710 of this embodiment is equipped with a container body 820 and a cover 822 , which is integrated with the container body 820 .
- the pharmaceutical composition container 710 is formed by adhering two laminated members 50 to each other.
- the container body 820 comprises a swallowing-aid substance chamber 830 , a first pharmaceutical composition chamber 834 and an apertured space 838 .
- the swallowing-aid substance chamber 830 and the first pharmaceutical composition chamber 834 are so formed as to maintain air tightness with respect to the external space around the pharmaceutical composition container 710 .
- a third pharmaceutical composition 84 is stored inside the first pharmaceutical composition chamber 834 . It is needless to say that the first pharmaceutical composition chamber 834 may also store a granular drug or another substance.
- a gas which does not have any effect on the third pharmaceutical composition 84 and the swallowing-aid substance 40 is filled into the swallowing-aid substance chamber 830 and the first pharmaceutical composition chamber 834 .
- the apertured space 838 is an empty chamber until the first weak seal 840 and the second weak seal 842 are broken.
- the apertured space 838 comprises an aperture.
- the portion between the swallowing-aid substance chamber 830 and the first pharmaceutical composition chamber 834 is partitioned by a first weak seal 840 .
- the portion between the first pharmaceutical composition chamber 834 and the apertured space 838 is partitioned by a second weak seal 842 .
- the strength of the first weak seal 840 and the second weak seal 842 is weaker than the strength of the bottom strong seal 860 and the side strong seal 862 .
- the usage method of the pharmaceutical composition container 710 of this embodiment is the same as the usage method of the pharmaceutical composition container 10 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here.
- the pharmaceutical composition container 710 of this embodiment produces the following three effects.
- the first effect is that it is possible to easily swallow a medicinal powder or another pharmaceutical composition.
- the second effect is that concerns regarding the stability of the drug become unnecessary.
- the third effect is that it is possible to improve the cleanliness during the ingestion of the third pharmaceutical composition 84 .
- FIG. 10 is a partial cross section of the pharmaceutical composition container 260 of this embodiment.
- the pharmaceutical composition container 260 of this embodiment is formed by double-folding one sheet made of a synthetic resin (low-density polyethylene, PET (polyethylene terephthalate) or another resin that is soft so as to be foldable and is heat-sealable, like composite resin), adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion.
- a synthetic resin low-density polyethylene, PET (polyethylene terephthalate) or another resin that is soft so as to be foldable and is heat-sealable, like composite resin
- the portion where the ends of the sheet are adhered to each other is the side strong seal 270 .
- the inside of the pharmaceutical composition container 260 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a first weak seal 300 , a second weak seal 302 and a third weak seal 304 .
- the first weak seal 300 comprises a first zone 311 , an intermediate chamber 312 and a second zone 314 .
- One of the spaces inside the pharmaceutical composition container 260 is the swallowing-aid substance chamber 280 .
- a swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 280 .
- the first zone 311 of the first weak seal 300 easily opens by means of the pressure received from the swallowing-aid substance 40 .
- the first zone 311 opens, the swallowing-aid substance 40 is pushed out into the intermediate chamber 312 .
- the second zone 314 , the second weak seal 302 and the third weak seal 304 sequentially open in the same way. This can be realized because the strength of the first weak seal 300 , the second weak seal 302 and the third weak seal 304 is weak compared to that of the side strong seal 270 .
- the first pharmaceutical composition chamber 282 and the second pharmaceutical composition chamber 284 exist.
- the first pharmaceutical composition chamber 282 and the second pharmaceutical composition chamber 284 store a first encapsulating item 212 or a second encapsulating item 213 .
- the pharmaceutical composition encapsulated by the first encapsulating item 212 stored in the first pharmaceutical composition chamber 282 and the pharmaceutical composition encapsulated by the second encapsulating item 213 stored in the second pharmaceutical composition chamber 284 are of different types.
- One of the spaces inside the pharmaceutical composition container 260 also contains an apertured space 286 .
- the apertured space 286 is provided on one end of the pharmaceutical composition container 260 and serves as the chute (in other words, the device for dropping the first encapsulating item 212 and the second encapsulating item 213 into the mouth of the patient) for the ingestion of the first encapsulating item 212 and the second encapsulating item 213 .
- the cover 288 Of the two ends of the pharmaceutical composition container 260 , the end on the opposite side of the end on which the apertured space 286 is provided, is the cover 288 .
- the boundary between the swallowing-aid substance chamber 280 and the cover 288 is the bottom strong seal 272 .
- the strength of the bottom strong seal 272 is the same as that of the side strong seal 270 ; therefore the bottom strong seal 272 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of the pharmaceutical composition container 260 .
- the portion which is more to the side of the second pharmaceutical composition chamber 284 than the cover 288 is referred to as the “container body.”
- FIG. 11 is an overview of the portion of the pharmaceutical composition container 260 of this embodiment which corresponds to the rear surface when viewed as shown in FIG. 10 . As is obvious from FIG. 11 , a label 262 is adhered to the pharmaceutical composition container 260 of this embodiment.
- the features unique to the pharmaceutical composition container 260 of this embodiment as compared to the pharmaceutical composition containers of the other embodiments are that: the cover 288 is disposed on one end and a cover insert portion 321 which is inserted into this cover 288 is disposed on the other end; the width of the pharmaceutical composition container 260 is larger on the base 331 of the portion which is inserted into the cover 238 ; the bottom strong seal 272 and a portion of the second weak seal 302 or a portion of the third weak seal 304 are folded over to insert the tip of the cover insert portion 321 into the cover 288 , and the base 331 is on the outside of the cover 288 .
- FIG. 12 shows the state where the cover insert portion 321 is inserted into the cover 238 and the base 331 is on the outside of the cover 238 .
- the portion of the base 331 is depressed; therefore it is possible to easily to pull out the cover insert portion 321 by inserting a finger thereinto.
- FIG. 13 is a view of the portion which corresponds to the rear surface when viewed as shown in FIG. 12 , in the state shown in FIG. 12 .
- the major part of the rear surface of the pharmaceutical composition container 260 is occupied by the label 262 .
- the cover insert portion 321 can easily be pulled out because a finger can be engaged with the base 331 of the cover insert portion 321 .
- composition container 260 of this embodiment produces the same effects like that of the embodiment 1.
- FIG. 14 is a partial cross section of the pharmaceutical composition container 400 of this embodiment.
- the pharmaceutical composition container 400 of this embodiment is formed by double-folding one sheet made of a synthetic resin, adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion.
- the portion where the ends of the sheet were adhered to each other is the side strong seal 410 .
- the inside of the pharmaceutical composition container 400 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a first weak seal 441 , a second weak seal 443 and a third weak seal 445 .
- the first weak seal 441 comprises a first zone 450 , an intermediate chamber 452 and a second zone 454 .
- One of these spaces is the swallowing-aid substance chamber 420 .
- a swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 420 .
- the first zone 450 and the second zone 454 sequentially open in the same way as the first weak seal 300 , the second weak seal 302 and the third weak seal 304 in the embodiment 6.
- the reason why the first zone 450 and the second zone 454 open in this way is the same as that in the embodiment 6.
- the first pharmaceutical composition chamber 422 and the second pharmaceutical composition chamber 424 exist.
- the first pharmaceutical composition chamber 422 and the second pharmaceutical composition chamber 424 store a first encapsulating item 212 or a second encapsulating item 213 .
- the pharmaceutical composition encapsulated by the first encapsulating item 212 stored in the first pharmaceutical composition chamber 422 and the pharmaceutical composition encapsulated by the second encapsulating item 213 stored in the second pharmaceutical composition chamber 424 are of different types.
- One of these spaces also contains an apertured space 426 .
- the apertured space 426 serves as the chute for the ingestion of the first encapsulating item 212 and the second encapsulating item 213 .
- the cover 428 Of the two ends of the pharmaceutical composition container 400 , the end on the opposite side of the end on which the apertured space 426 is provided, is the cover 428 .
- the boundary between the swallowing-aid substance chamber 420 and the cover 478 is the bottom strong seal 412 .
- the strength of the bottom strong seal 412 is the same as that of the side strong seal 410 ; therefore the bottom strong seal 412 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of the pharmaceutical composition container 400 .
- the cover 478 is disposed on one end; the bottom strong seal 412 and the base of the portion where the apertured space 426 is disposed are folded over to insert the portion where the apertured space 426 is disposed into the cover 478 ; the tip 480 of the portion where the apertured space 426 is disposed is round; and a part of the edge 482 of the cover 478 is cut out.
- the portion which is more to the side of the second pharmaceutical composition chamber 424 than the cover 478 is referred to as the “container body.”
- the one of the two ends of the pharmaceutical composition container 400 on which the apertured space 426 is disposed is pulled out of the cover 478 .
- the subsequent usage method is the same as in the other embodiments.
- FIG. 15 shows the state in which pharmaceutical composition container 400 is folded over during production. After the pharmaceutical composition container 400 is folded over, the portion where the apertured space 426 is disposed is inserted into the cover 478 . At this time, the tip 480 of the portion where the apertured space 426 is disposed gets caught at any position of the cut-out edge 482 of the cover 478 and opens the mouth of the cover 478 . Since the mouth of the cover 478 is opened, the tip 480 smoothly enters the inside of the cover 478 .
- FIG. 16 shows the pharmaceutical composition container 400 after the portion where the apertured space 426 is disposed is inserted into the cover 478 .
- composition container 400 of this embodiment produces the same effects like that of the embodiment 1.
- FIG. 17 is a partial cross section of the pharmaceutical composition container 500 of this embodiment.
- the pharmaceutical composition container 500 of this embodiment is formed by double-folding one sheet made of a synthetic resin, adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion.
- the portion where the ends of the sheet are adhered to each other is the side strong seal 511 .
- the inside of the pharmaceutical composition container 500 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a first weak seal 540 , a second weak seal 542 and a third weak seal 544 .
- the first weak seal 540 comprises a first zone 550 , an intermediate chamber 552 and a second zone 554 .
- One of the spaces inside the pharmaceutical composition container 500 is the swallowing-aid substance chamber 521 .
- a swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 521 .
- the first zone 550 and the second zone 554 sequentially open in the same way as the first weak seal 300 , the second weak seal 302 and the third weak seal 304 in the embodiment 6.
- the reason why the first zone 550 and the second zone 554 open in this way is the same as that in the embodiment 6.
- the first pharmaceutical composition chamber 523 and the second pharmaceutical composition chamber 524 exist.
- the first pharmaceutical composition chamber 523 and the second pharmaceutical composition chamber 524 store a first encapsulating item 212 or a second encapsulating item 213 .
- the pharmaceutical composition encapsulated by the first encapsulating item 212 stored in the first pharmaceutical composition chamber 523 and the pharmaceutical composition encapsulated by the second encapsulating item 213 stored in the second pharmaceutical composition chamber 524 are of different types.
- One of these spaces also contains an apertured space 526 .
- the apertured space 526 serves as the chute for the ingestion of the first encapsulating item 212 and the second encapsulating item 213 .
- the cover 528 Of the two ends of the pharmaceutical composition container 500 , the end on the opposite side of the end on which the apertured space 526 is provided, is the cover 528 .
- the boundary between the swallowing-aid substance chamber 521 and the cover 528 is the bottom strong seal 512 .
- the strength of the bottom strong seal 512 is the same as that of the side strong seal 511 ; therefore the bottom strong seal 512 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of the pharmaceutical composition container 500 .
- the portion which is more to the side of the second pharmaceutical composition chamber 524 than the cover 528 is referred to as the “container body.”
- FIG. 18 is a partial cross section showing one end of the pharmaceutical composition container 500 during the production thereof.
- FIG. 19 is a perspective view showing one end of the pharmaceutical composition container 500 during the production thereof.
- the features unique to the pharmaceutical composition container 500 as compared to the pharmaceutical composition containers of the other embodiments will be explained while referring to FIG. 18 and FIG. 19 .
- the features thereof are that: the bottom strong seal 512 and the base of the portion where the apertured space 526 is disposed are folded over to insert the portion where the apertured space 526 is disposed into the cover 528 ; and a melt-bonding margin 514 is disposed on the tip portion 516 which is inserted into the cover 528 on the side strong seal 511 .
- This melt-bonding margin 514 is folded back like shown in FIG. 19 and melt-bonded to the tip portion 516 .
- the usage method of the pharmaceutical composition container 500 of this embodiment is the same as that of the embodiment 7.
- composition container 500 of this embodiment produces the same effects like that of the embodiment 1.
- FIG. 20 is a partial cross section of the pharmaceutical composition container 351 of this embodiment.
- the pharmaceutical composition container 351 of this embodiment is formed by double-folding one sheet made of a synthetic resin, adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion.
- the portion where the ends of the sheet are adhered to each other is the side strong seal 361 .
- the inside of the pharmaceutical composition container 351 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a first weak seal 390 , a second weak seal 392 and a predetermined aperture part 394 .
- the first weak seal 390 comprises a first zone 401 , an intermediate chamber 403 and a second zone 405 .
- One of the spaces inside the pharmaceutical composition container 351 is the swallowing-aid substance chamber 370 .
- a swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 370 .
- the first zone 401 and the second zone 405 sequentially open in the same way as the first weak seal 300 , the second weak seal 302 and the third weak seal 304 in the embodiment 6.
- the reason why the first zone 401 and the second zone 405 open in this way is the same as that in the embodiment 6.
- the first pharmaceutical composition chamber 372 and the second pharmaceutical composition chamber 374 exist.
- a first encapsulating item 212 is stored in the first pharmaceutical composition chamber 372 .
- a known tablet 352 is stored in the second pharmaceutical composition chamber 374 .
- the cover 378 Of the two ends of the pharmaceutical composition container 351 , the end on the opposite side of the end on which the predetermined aperture part 394 is provided, is the cover 378 .
- the boundary between the swallowing-aid substance chamber 370 and the cover 378 is the bottom strong seal 362 .
- the strength of the bottom strong seal 362 is the same as that of the side strong seal 361 ; therefore the bottom strong seal 362 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of the pharmaceutical composition container 351 .
- the portion which is more to the side of the second pharmaceutical composition chamber 374 than the cover 378 is referred to as the “container body.”
- FIG. 21 is an external view of the pharmaceutical composition container 351 at this time.
- the features unique to the pharmaceutical composition container 351 as compared to the pharmaceutical composition containers of the other embodiments are that: the portion 354 which is inserted into the cover 378 is provided with a predetermined aperture part 394 ; and the seal strength of that predetermined aperture part 394 is weaker than the seal strength of the side strong seal 361 .
- the usage method of the pharmaceutical composition container 351 of this embodiment is the same as that of the embodiment 7.
- the seal strength of the predetermined aperture part 394 is weaker than the seal strength of the side strong seal 361 .
- the predetermined aperture part 394 opens when the portion 354 where the predetermined aperture part 394 is disposed is put into the mouth of the patient and the pharmaceutical composition container 351 is squeezed. Thereby the aperture is formed.
- the aperture interconnects the outside of the pharmaceutical composition container 351 with the spaces.
- composition container 351 of this embodiment produces the same effects like that of the embodiment 1.
- the abovementioned pharmaceutical composition containers 10 , 210 , 260 , 310 , 351 , 400 , 500 , 510 and 710 are presented as examples to concretize the technical concept of this invention.
- the material properties of the container body 20 , 220 and 320 are not limited to the abovementioned embodiments.
- the shape of the container bodies 20 , 220 , 320 , 520 and 720 , the shape of the spaces, the shape of the aperture, the dimensions, structures and positioning thereof are not limited to those mentioned in the abovementioned embodiments. It is possible to apply various changes to the pharmaceutical composition containers 10 , 210 , 260 , 310 , 351 , 400 , 500 , 510 and 710 explained in these embodiments within the scope of the technical concept of this invention.
- the form of the first encapsulating item 42 and the second encapsulating item 44 is not limited to the above-mentioned form.
- the shape thereof may be rectangular.
- publicly known capsules may also be stored.
- the shape of the spaces comprised in the container bodies 20 , 220 , 320 , 520 and 720 is not particularly limited.
- the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 shown in FIG. 1 have a hexagonal shape, but these chambers may also have a triangular, quadrangular, pentagonal, heptagonal or other polygonal shape, or a circular or oval shape.
- the number of the spaces comprised in the container bodies 20 , 220 and 320 may be four or more.
- a chamber of the same kind as the intermediate chamber 32 of the embodiment 1 may also be disposed in the pharmaceutical composition container 210 of the embodiment 2, the pharmaceutical composition container 310 of the embodiment 3 or the pharmaceutical composition container 710 of the embodiment 5.
- the intermediate chamber 32 in the embodiment 1 is not a mandatory space.
- the container body 20 of the embodiment 1 and the container body 320 of the embodiment 3 are not limited to being formed by adhering two sheets to each other.
- the container body 220 of the embodiment 2 is not limited to being formed by adhering the outer edge of one sheet.
- the container body 220 of the embodiment 2 may also be formed by adhering two sheets to each other.
- the container body 20 of the embodiment 1 and the container body 320 of the embodiment 3 may also be formed by double-folding one sheet and adhering the outer edges to each other.
- the pharmaceutical composition is a powdered or granular preparation and the swallowing-aid substance is a jelly; however, it is needless to say that the pharmaceutical composition and swallowing-aid substance applied to this invention are not limited thereto.
- the pharmaceutical composition may be a tablet, a capsule or a simple block.
- the pharmaceutical composition does not have to be stored in the first pharmaceutical composition chamber 34 or the second pharmaceutical composition chamber 36 in the form of an encapsulating item. That is to say, the pharmaceutical composition does not have to be wrapped in a wafer or other wrapping material.
- the item formed as the pharmaceutical composition is not limited to an item that is usually treated as a medical drug.
- the item formed as the pharmaceutical composition may also be a food which is recognized for its effect of improving the health state.
- the swallowing-aid substance may be an aqueous solution, or may also be honey, custard cream, peanut butter, cheese spread or the like. However, it is preferable that the swallowing-aid substance have a fluidity of a degree that allows the swallowing-aid substance to move around the spaces provided in the container body in the environment where the pharmaceutical composition container is used.
- the combined drug may be stored in one pharmaceutical composition chamber.
- the combined drug mentioned here indicates a mixture.
- an encapsulating item is stored in the pharmaceutical composition container, it is possible to use, as the material for that encapsulating item, a wafer made of starch with a thickness of 15 ⁇ m as mentioned above, or a variety of other materials conventionally known as edible film materials.
- the types of these materials include polysaccharides (for example, pullulan, arabinoxylan, decomposition products of guar gum, sodium alginate, carrageenan, agar-agar, pectin, cellulose, etc.) and peptide-based substances (for example, gelatin, decomposition products of silk protein, decomposition products of casein, etc.). Those materials may be used on a standalone basis or as a combination of two or more types.
- the pharmaceutical composition container of this invention is suitable for the use as, for example, a container for the ingestion of a drug.
- the pharmaceutical composition container of this invention is suitable for the use as a container for the ingestion of a drug, wherein the drug is filled into the container by a system as mentioned below.
- a system is one wherein a plurality of auger filling machines are set up, a transport system and weighing system are added, the filling machines, the transport system and the weighing system are connected to a medical-drug production line and automatic operation is performed over a long time.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The cleanliness when a pharmaceutical composition is swallowed is improved. A pharmaceutical composition container 10 is equipped with at least three spaces 30, 32, 34, 36 and 38 inside a container body 20. The pharmaceutical composition container 10 is further equipped with a cover 22. The portions 140, 142, 144 and 146 between two adjoining spaces are sealed. The portions 140, 142, 144 and 146 between two adjoining spaces open when force is applied from the outside of the pharmaceutical composition container 10. At least one of the spaces is an apertured space 38, which comprises an aperture 60. A swallowing-aid substance 40 is stored in a swallowing-aid substance chamber 30, which is at least one of the spaces. Pharmaceutical compositions 80 and 82 are stored in pharmaceutical composition chambers 34 and 36, each of which is at least one of the spaces. Of the container body 20, the portion forming the apertured space 38 is covered by a cover 22.
Description
- This invention relates to a pharmaceutical composition container; more specifically, to a pharmaceutical composition container so configured as to allow the improvement of cleanliness when the pharmaceutical composition is swallowed.
- Patent document 1 discloses a multi-chamber container. This multi-chamber container is so partitioned into a plurality of spaces as to enable the spaces to be interconnected with each other. The spaces are sealed in such a state that they can be interconnected with each other by means of force applied from the outside. A granular agent is stored in a tightly sealed state in any of the spaces. A thick fluid substance is stored in a tightly sealed state in one or more other spaces. After interconnecting the spaces with each other and gathering and mixing the granular agent with the thick fluid substance, it is possible to take out the mixture from a take-out port provided on any of the spaces.
- According to the container disclosed in patent document 1, it is possible to ingest a granular agent by means of an extremely simple operation. Moreover, according to the multi-chamber container disclosed in patent document 1, it is possible to significantly reduce the resistance of the patient towards taking the medication.
-
- Patent document 1: Japanese Patent Laid-Open No. 10-234820
- However, the invention disclosed in patent document 1 bears the problem that it is highly probable that bacteria or other matter having an adverse effect on the patient enter the body of the patient when the patient takes the granular agent.
- The technical issue addressed by this invention is intended to solve the abovementioned problem, and the purpose of the invention is to provide a pharmaceutical composition container that allows the improvement of cleanliness when the pharmaceutical composition is swallowed.
- The pharmaceutical composition container of this invention is explained in reference to the drawings. Note that the use of the reference numerals of the drawings in this column is intended to facilitate the understanding of the content of the invention and is not intended to limit the content to the scope indicated.
- According to the aspects of this invention in order to achieve the abovementioned purpose, the pharmaceutical composition container (10) is equipped with at least three spaces (30, 32, 34, 36, 38) inside a container body (20). The pharmaceutical composition container (10) is further equipped with a cover (22). The portions (140, 142, 144, 146) between two adjoining spaces are sealed. The portions (140, 142, 144, 146) between two adjoining spaces open when force is applied from the outside of the pharmaceutical composition container (10). At least one of the spaces is a apertured space (38), which comprises an aperture (60). A swallowing-aid substance (40) is stored in a swallowing-aid substance chamber (30), which is at least one of the spaces. Pharmaceutical compositions (80, 82) are stored in pharmaceutical composition chambers (34, 36), each of which is at least one of the spaces. Of the container body (20), the portion forming the apertured space (38) is covered by a cover (22).
- The portions (140, 142, 144, 146) between two adjoining spaces are sealed. When a force is applied thereto from the outside of the pharmaceutical composition container (10), the portions (140, 142, 144, 146) open. By the opening of the portions (140, 142, 144, 146), the swallowing-aid substance (40) can be guided from the swallowing-aid substance chamber (30) to the pharmaceutical composition chambers (34, 36). When the swallowing-aid substance (40) is guided to the pharmaceutical composition chambers (34, 36), the pharmaceutical compositions (80, 82) are mixed with the swallowing-aid substance (40). Thereby, when holding the aperture (60) against the mouth of a person and pushing out the swallowing-aid substance (40) and the pharmaceutical compositions (80, 82) from this aperture (60), a mixture of the pharmaceutical compositions (80, 82) and the swallowing-aid substance (40) will enter the mouth of the person and be swallowed. By the way, of the container body (20), the portion forming the apertured space (38) is covered by a cover (22) before that portion is held against the mouth of a person. Therefore, the cleanliness of this portion is maintained at a very high level. As a result, it is possible to improve the cleanliness when the pharmaceutical composition is swallowed.
- Further, it is preferable that the abovementioned cover (22) be integrated with the container body (20).
- Or, it is preferable that the abovementioned at least three spaces (30, 32, 34, 36, 38) and the cover (22) be arranged so as to form one row. In this case, the apertured space (38) is disposed on one end of the row. The cover (22) is disposed on the other end of the row. The container body (20) and the cover (22) can be folded over, and folding over the container body (20) and the cover (22) brings the aperture (60) and the cover (22) into a state of facing each other.
- Moreover, it is preferable that the encapsulating items (42, 44) be stored in the abovementioned pharmaceutical composition chambers (34, 36). In this case, at least the surface of the encapsulating items (42, 44) melts in the ingredients of the swallowing-aid substance (40). The encapsulating items (42, 44) contain the pharmaceutical compositions (80, 82).
- When the swallowing-aid substance (40) is guided into the pharmaceutical composition chambers (34, 36), at least the surface of the encapsulating items (42, 44) melts in the swallowing-aid substance (40). Thereby, when holding the aperture (60) against the mouth of a person with swallowing difficulties and pushing out the swallowing-aid substance (40) and the encapsulating items (42, 44) from this aperture (60), the encapsulating items (42, 44) will enter the mouth of the person with swallowing difficulties while being enclosed in swallowing-aid substance (40). At this time, the surface of encapsulating items (42, 44) has melted. The encapsulating items (42, 44) can easily be swallowed even by a person with swallowing difficulties because the encapsulating items (42, 44) are enclosed in the swallowing-aid substance (40) and the surface of encapsulating items (42, 44) has melted. This means that the pharmaceutical compositions (80, 82) are also swallowed with the swallowing of the encapsulating items (42, 44). However, the pharmaceutical compositions (80, 82) in the encapsulating items (42, 44) do not scatter until the encapsulating items (42, 44) have sufficiently melted. Moreover, by enclosing the pharmaceutical compositions (80, 82) with encapsulating items (42, 44), it is possible to reduce the residual quantity of the pharmaceutical compositions (80, 82) inside the pharmaceutical composition chambers (34, 36).
- According to the other aspects of this invention, the pharmaceutical composition container (351) is equipped with a plurality of spaces (370, 372, 374) inside the container body. The container body is provided with a predetermined aperture part (394), wherein an aperture is to be formed. The aperture is opened when force is applied to the pharmaceutical composition container (351) from the outside, thereby interconnecting the outside of the pharmaceutical composition container (351) with the space. The portions (390, 392) between two adjoining spaces of spaces (370, 372, 374) are sealed. The portions (390, 392) between two adjoining spaces of spaces (370, 372, 374) open when force is applied from the outside of the pharmaceutical composition container (351). A swallowing-aid substance (40) is stored in a swallowing-aid substance chamber (370), which is at least one of the spaces. A pharmaceutical composition is stored in pharmaceutical composition chambers (372, 374), which are at least one of the spaces. The container body can be folded over. The pharmaceutical composition container (351) is further equipped with a cover (378). The cover (378) is disposed so as to adjoin the container body. The cover (378) is integrated with the container body. The cover (378) allows pulling out or inserting the portion (354) of the container body which is provided with the predetermined aperture part (394). The portion (354) which is provided with the predetermined aperture part (394) is covered by the cover (378).
- According to this invention, it is possible to improve the cleanliness when the pharmaceutical composition is swallowed.
-
FIG. 1 is a partial cross section of the pharmaceutical composition container of the embodiment 1 of this invention. -
FIG. 2 is a cross section of the pharmaceutical composition container of the embodiment 1 of this invention. -
FIG. 3 is an enlarged cross section of the pharmaceutical composition container of the embodiment 1 of this invention. -
FIG. 4 shows the production procedure for the pharmaceutical composition container of the embodiment 1 of this invention. -
FIG. 5 shows the usage method of the pharmaceutical composition container of the embodiment 1 of this invention. -
FIG. 6 is a partial cross section of the pharmaceutical composition container of the embodiment 2 of this invention. -
FIG. 7 is a partial cross section of the pharmaceutical composition container of the embodiment 3 of this invention. -
FIG. 8 is a partial cross section of the pharmaceutical composition container of the embodiment 4 of this invention. -
FIG. 9 is a partial cross section of the pharmaceutical composition container of the embodiment 5 of this invention. -
FIG. 10 is a partial cross section of the pharmaceutical composition container of the embodiment 6 of this invention. -
FIG. 11 is an external view of the pharmaceutical composition container of the embodiment 6 of this invention. -
FIG. 12 shows a state of the embodiment 6 of this invention wherein the cover insert portion is inserted into the cover and the base is on the outside of the cover. -
FIG. 13 is a rear view of the state in the embodiment 6 of this invention wherein the cover insert portion is inserted into the cover. -
FIG. 14 is a partial cross section of the pharmaceutical composition container of the embodiment 7 of this invention. -
FIG. 15 shows the state of the embodiment 7 of this invention wherein the pharmaceutical composition container is folded. -
FIG. 16 shows the state of the embodiment 7 of this invention after one end of the pharmaceutical composition container was inserted into the cover. -
FIG. 17 is a partial cross section of the pharmaceutical composition container of the embodiment 8 of this invention. -
FIG. 18 is a partial cross section showing one end of the pharmaceutical composition container of the embodiment 8 of this invention during the production thereof. -
FIG. 19 is a perspective view showing one end of the pharmaceutical composition container of the embodiment 8 of this invention during the production thereof. -
FIG. 20 is a partial cross section of the pharmaceutical composition container of the embodiment 9 of this invention. -
FIG. 21 is an external view of the state of the embodiment 9 of this invention wherein one end of the pharmaceutical composition container is inserted into the cover. - The following explains the embodiments of this invention on the basis of the drawings. In the following explanations, identical parts are assigned the same reference numeral. The names and functions thereof are also the same. Accordingly, detailed explanations thereof will not be repeated.
- The following explains the
pharmaceutical composition container 10 of the embodiment 1 of this invention. - The configuration of the
pharmaceutical composition container 10 of this embodiment will be explained while referring toFIG. 1 . Thepharmaceutical composition container 10 of this embodiment is equipped with acontainer body 20 and acover 22, which is integrated with thecontainer body 20. Thecontainer body 20 and thecover 22 of this embodiment are formed by adhering twolaminated members 50 to each other. Thelaminated member 50 will be explained later. - The
container body 20 is equipped with a swallowing-aid substance chamber 30, anintermediate chamber 32, a firstpharmaceutical composition chamber 34, a secondpharmaceutical composition chamber 36 and anapertured space 38. The swallowing-aid substance chamber 30, theintermediate chamber 32, the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 are so formed as to maintain air tightness with respect to the external space around thepharmaceutical composition container 10. - The
cover 22, the swallowing-aid substance chamber 30, theintermediate chamber 32, the firstpharmaceutical composition chamber 34, the secondpharmaceutical composition chamber 36 and theapertured space 38 are so arranged as to form one row. As is obvious fromFIG. 1 , theapertured space 38 is disposed on one end of that row. Thecover 22 is disposed on the other end of that row.FIG. 2 is a cross section of thepharmaceutical composition container 10 of this embodiment. In the mode shown inFIG. 2 , thecover 22 can cover the outside of the portion of thecontainer body 20 which forms theapertured space 38. This is possible because thelaminated member 50 of this embodiment can be folded over. - The items stored in the swallowing-
aid substance chamber 30, the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 are explained while again referring toFIG. 1 . - A swallowing-
aid substance 40 is stored inside the swallowing-aid substance chamber 30. The swallowing-aid substance 40 in this embodiment is a sterilized jelly containing water. The water content of the jelly in this embodiment is established in such a manner that the following requirement is fulfilled. The requirement is that it must be possible to provide at least two minutes from the time when the swallowing-aid substance 40 covers the surface of thefirst encapsulating item 42 and thesecond encapsulating item 44, which will be explained later, until the time when thefirst encapsulating item 42 and thesecond encapsulating item 44 completely melt. - A
first encapsulating item 42 is stored inside the firstpharmaceutical composition chamber 34. A granular drug or another firstpharmaceutical composition 80 is encapsulated inside thefirst encapsulating item 42. The material of thefirst encapsulating item 42 in this embodiment is a wafer which is made of starch and has a thickness of 15 μm. - A
second encapsulating item 44 is stored inside the secondpharmaceutical composition chamber 36. Asecond pharmaceutical composition 82 is encapsulated inside thesecond encapsulating item 44. The secondpharmaceutical composition 82 is a substance of a type that is different to that of the granular firstpharmaceutical composition 80. The material of thesecond encapsulating item 44 in this embodiment is a wafer which is made of starch and has a thickness of 10 μm. The openings of thefirst encapsulating item 42 and thesecond encapsulating item 44 are sealed by the twisting of the portions corresponding to the inlets for the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82. - That a wafer is used as the material for the
first encapsulating item 42 and thesecond encapsulating item 44 is because thefirst encapsulating item 42 and thesecond encapsulating item 44 are required to have the following function. The function is that, when the swallowing-aid substance 40 covers the surface of thefirst encapsulating item 42 or thesecond encapsulating item 44, the surface thereof must start to melt, and after thefirst encapsulating item 42 and thesecond encapsulating item 44 are swallowed, thefirst encapsulating item 42 and thesecond encapsulating item 44 must completely melt. That the wafer used for thefirst encapsulating item 42 is thicker than the wafer used for thesecond encapsulating item 44 is because the time from when the wafer begins to be covered by the swallowing-aid substance 40 until the wafer completely melts is required to be set to a longer time for thefirst encapsulating item 42 than for thesecond encapsulating item 44. The reason for this requirement is that thefirst encapsulating item 42 is covered by the swallowing-aid substance 40 earlier than thesecond encapsulating item 44. That a wafer of a thickness of 10 μm is used as the material for thesecond encapsulating item 44 is in order to provide at least two minutes of time from when thesecond encapsulating item 44 is covered by the swallowing-aid substance 40 until thesecond encapsulating item 44 completely melts. Naturally, the thickness of the wafer should be selected as appropriate depending on the material properties thereof. - Note that, if necessary, a gas (for example, nitrogen gas) which does not have any effect on the first
pharmaceutical composition 80, the secondpharmaceutical composition 82 and the swallowing-aid substance 40, is filled into the first swallowing-aid substance chamber 30, the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36. - Further, the
intermediate chamber 32 and theapertured space 38 of this embodiment are empty chambers until the firstweak seal 140 to fourthweak seal 146, which will be explained later, are broken. An empty chamber is a space in which nothing is stored, or in which a gas is stored that does not have any effect on the firstpharmaceutical composition 80, the secondpharmaceutical composition 82 or the swallowing-aid substance 40. Theapertured space 38 comprises anaperture 60. Theaperture 60 interconnects the outside of the swallowing-aid substance chamber 30, theintermediate chamber 32, the firstpharmaceutical composition chamber 34, the secondpharmaceutical composition chamber 36 and theapertured space 38 with the inside thereof. However, until every one of the firstweak seal 140 to fourthweak seal 146 is broken, theaperture 60 interconnects the inside of those of the swallowing-aid substance chamber 30, theintermediate chamber 32, the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 which are interconnected with theapertured space 38, with the outside of those spaces. - The portion between the swallowing-
aid substance chamber 30 and theintermediate chamber 32 is partitioned by a firstweak seal 140. The portion between theintermediate chamber 32 and the firstpharmaceutical composition chamber 34 is partitioned by a secondweak seal 142. The portion between the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 is partitioned by a thirdweak seal 144. The portion between the secondpharmaceutical composition chamber 36 and theapertured space 38 is partitioned by a fourthweak seal 146. The firstweak seal 140, the secondweak seal 142, the thirdweak seal 144 and the fourth weak seal 146 (these are referred to as “firstweak seal 140 to fourthweak seal 146”) are disposed in the portions between two adjoining spaces of the spaces provided in thecontainer body 20. - The strength of the first
weak seal 140 to fourthweak seal 146 is weaker than the strength of the bottomstrong seal 160 and the sidestrong seal 162. The bottomstrong seal 160 is the portion on the boundary between thecontainer body 20 and thecover 22 where the surfaces of thelaminated members 50 are adhered to each other. The sidestrong seal 162 is the portion where the surfaces of thelaminated members 50 are adhered to each other excluding the firstweak seal 140 to fourthweak seal 146 and the bottomstrong seal 160. In the case of this embodiment, the strength of the firstweak seal 140 to fourthweak seal 146 is such that the firstweak seal 140 to fourthweak seal 146 can be broken by the pressure of the swallowing-aid substance 40 (this pressure being caused by the application of force by an adult person from the outside of the swallowing-aid substance chamber 30). The specific method for breaking the portion between the swallowing-aid substance chamber 30 and theintermediate chamber 32, the portion between theintermediate chamber 32 and the firstpharmaceutical composition chamber 34, the portion between the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 and the portion between the secondpharmaceutical composition chamber 36 and theapertured space 38 is not limited to breaking by means of pressure from the swallowing-aid substance 40. For example, the firstweak seal 140 to fourthweak seal 146 may also be ripped apart by holding one of the twolaminated members 50 in each hand and pulling the laminated members apart. -
FIG. 3 is an enlarged cross section of thepharmaceutical composition container 10 of this embodiment. The configuration of thelaminated member 50 and the configuration of the firstweak seal 140 to fourthweak seal 146 will be explained while referring toFIGS. 1 and 3 . Thelaminated member 50 of this embodiment comprises anouter skin member 100, anintermediate member 102 and a sealing member 104 (note that this three-layered structure of thelaminated member 50 is not depicted (is omitted) inFIG. 2 ). The sealingmembers laminated members 50 are fusion-bonded to each other. This fusion-bonded portion is broken prior to theouter skin member 100 and theintermediate member 102 by force applied from the outside of thepharmaceutical composition container 10. Compared to the fusing point of theouter skin member 100 and the fusing point of theintermediate member 102, the fusing point of the sealingmember 104 is low. For this reason, the sealingmember 104 melts before theouter skin member 100 and theintermediate member 102 melt when heat is applied to thelaminated member 50 from the outside of theouter skin member 100. Since the sealingmember 104 melts before theouter skin member 100 and theintermediate member 102 melt, it is possible to fusion-bond only the sealingmember 104. These fusion-bonded portions are the firstweak seal 104 to fourthweak seal 146.FIG. 3 shows only the fourthweak seal 146. - The material of those portions of the sealing
member 104 that correspond to the firstweak seal 140 to fourthweak seal 146 is different from the material of those portions of the sealingmember 104 that correspond to the bottomstrong seal 160 and the side strong seal 162 (however, the material of theouter skin member 100 and the material of theintermediate member 102 are the same between the portion corresponding to the firstweak seal 140 to fourthweak seal 146 and the portion corresponding to the bottomstrong seal 160 and the side strong seal 162). Since the materials are different, it is possible to make the strength of the firstweak seal 140 to fourthweak seal 146 weaker than the strength of the bottomstrong seal 160 and the sidestrong seal 162. As a side note, in this embodiment, the material of theouter skin member 100 is polyethylene terephthalate. The material of theintermediate member 102 is nylon. The material of those portions of the sealingmember 104 which correspond to the firstweak seal 140 to fourthweak seal 146 is polyethylene. -
FIG. 4 shows the production procedure for thepharmaceutical composition container 10 of this embodiment. The production procedure for thepharmaceutical composition container 10 will be explained while referring toFIG. 4 . In the first step, the twolaminated members pharmaceutical composition container 10 is heated. Thereby, as is shown inFIG. 4 (A), the sidestrong seal 162 is formed. In the second step, the periphery of theintermediate chamber 32 on thelaminated member 50 is heated. Thereby, as is shown inFIG. 4 (B), the firstweak seal 140 and the secondweak seal 142 are formed. In the third step, thefirst encapsulating item 42 is inserted between the twolaminated members FIG. 4 (C). In the fourth step, the periphery of the portion between the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 on thelaminated member 50 is heated. Thereby, as is shown inFIG. 4 (D), the thirdweak seal 144 is formed. In the fifth step, thesecond encapsulating item 44 is inserted between the twolaminated members FIG. 4 (E). In the sixth step, the periphery of the portion between the secondpharmaceutical composition chamber 36 and theapertured space 38 on thelaminated member 50 is heated. Thereby, as is shown inFIG. 4 (F), the fourthweak seal 146 is formed. In the seventh step, the swallowing-aid substance 40 is filled between the twolaminated members weak seal 140 on thecontainer body 20 is folded over, and the swallowing-aid substance chamber 30 is oriented upwards. When the swallowing-aid substance chamber 30 is oriented upwards, a nozzle, which is not shown in the drawing, is inserted into the swallowing-aid substance chamber 30 to fill in the swallowing-aid substance 40. In the eighth step, the boundary portion between thecontainer body 20 and thecover 22 is heated. Thereby, as is shown inFIG. 4 (G), the bottomstrong seal 160 is formed. In the ninth step, the boundary portion between thecontainer body 20 and thecover 22 is folded over as shown inFIG. 4 (H), and then the portion of thecontainer body 20 which forms theapertured space 38 is inserted between thecover 22. Thepharmaceutical composition container 10 which is completed through these steps is packed into a carton box which is not shown in the drawings, and distributed. -
FIG. 5 shows the usage method of thepharmaceutical composition container 10 of this embodiment. The procedure for taking the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 out of thepharmaceutical composition container 10 and ingesting the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 will be explained while referring toFIG. 5 . - First, the caretaker etc. pulls the tip portion of the
container body 20 out of thecover 22, thereby bringing thepharmaceutical composition container 10, which had been in the state shown inFIG. 4 (H), into the state shown inFIG. 1 orFIG. 4 (G). Next, the caretaker etc. presses the swallowing-aid substance chamber 30 from the outside of thepharmaceutical composition container 10 to break the firstweak seal 140 by means of the pressure from inside the swallowing-aid substance chamber 30. When the firstweak seal 140 is broken, the swallowing-aid substance 40 is pushed out into theintermediate chamber 32. The swallowing-aid substance 40 that was pushed out fills the inside of theintermediate chamber 32. - When the caretaker etc. continues to press the swallowing-
aid substance chamber 30 from the outside of thepharmaceutical composition container 10 in this state, the secondweak seal 142 is broken by the pressure of the swallowing-aid substance 40 inside theintermediate chamber 32. At this time, the caretaker etc. folds thecover 22 towards thecontainer body 20. When the secondweak seal 142 is broken, the swallowing-aid substance 40 is pushed out into the firstpharmaceutical composition chamber 34. The swallowing-aid substance 40 that was pushed out fills the inside of the firstpharmaceutical composition chamber 34. From this time, the surface of thefirst encapsulating item 42 starts to melt in the swallowing-aid substance 40. - After the swallowing-
aid substance 40 is pushed out into the firstpharmaceutical composition chamber 34, the caretaker etc. lets thepatient 200 put thepharmaceutical composition container 10 into the mouth. When thepharmaceutical composition container 10 is taken into the mouth, thepatient 200 folds thecover 22, which was folded back towards thecontainer body 20, further towards thecontainer 20 and squeezes thecontainer body 20 and thecover 22. Thereby, pressure is applied to the swallowing-aid substance 40. As a result from the pressure applied to the swallowing-aid substance 40, the thirdweak seal 144 breaks. When the thirdweak seal 144 is broken, the swallowing-aid substance 40 is pushed out together with thefirst encapsulating item 42 into the secondpharmaceutical composition chamber 36. The swallowing-aid substance 40 that was pushed out fills the inside of the secondpharmaceutical composition chamber 36. From this time, the surface of thesecond encapsulating item 44 also starts to melt in the swallowing-aid substance 40. - After the swallowing-
aid substance 40 is pushed out into the secondpharmaceutical composition chamber 36, thepatient 200 folds back thecontainer body 20 and thecover 22 from the swallowing-aid substance chamber 30 further towards the secondpharmaceutical composition chamber 36 and further squeezes same. Thereby, pressure is applied to the swallowing-aid substance 40. As a result from the pressure applied to the swallowing-aid substance 40, the fourthweak seal 146 breaks. When the fourthweak seal 146 is broken, the swallowing-aid substance 40, thefirst encapsulating item 42 and thesecond encapsulating item 44 are pushed out into theapertured space 38. The swallowing-aid substance 40, thefirst encapsulating item 42 and thesecond encapsulating item 44 are swallowed via theapertured space 38 and the mouth of thepatient 200. At this time, the surfaces of thefirst encapsulating item 42 and thesecond encapsulating item 44 have melted in the ingredients of the swallowing-aid substance 40; therefore the surfaces of thefirst encapsulating item 42 and thesecond encapsulating item 44 are now slippery. Because the surfaces of thefirst encapsulating item 42 and thesecond encapsulating item 44 are slippery, thefirst encapsulating item 42 and thesecond encapsulating item 44 are swallowed smoothly. - In this way, the
pharmaceutical composition container 10 of this embodiment produces the following eight effects. The first effect is that it is possible to easily swallow the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82. The second effect is that, if the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 have a bitter taste, that bitter taste is suppressed. The third effect is that it is possible to suppress the scattering of the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 in the mouth. The fourth effect is that concerns regarding the stability of the first pharmaceutical composition and the secondpharmaceutical composition 82 become unnecessary. The fifth effect is that it is possible to let patients with swallowing difficulties ingest solids of various types. The sixth effect is that it is possible to improve the cleanliness during the ingestion of the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82. The seventh effect is that it is possible to smoothly push out thefirst encapsulating item 42 and thesecond encapsulating item 44. The eighth effect is that it is possible to reduce the residual quantity of thepharmaceutical compositions - The first effect will now be explained in detail. The
first encapsulating item 42 and thesecond encapsulating item 44 enter the mouth of thepatient 200 while being enclosed in the swallowing-aid substance 40. At this time, the surfaces of thefirst encapsulating item 42 and thesecond encapsulating item 44 have melted. Thefirst encapsulating item 42 and thesecond encapsulating item 44 can easily be swallowed even by a person with swallowing difficulties because thefirst encapsulating item 42 and thesecond encapsulating item 44 are enclosed in the swallowing-aid substance 40 and the surfaces thereof have melted. Since thepharmaceutical composition 80 is inside thefirst encapsulating item 42 and thesecond encapsulating item 44, the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 are also swallowed when thefirst encapsulating item 42 and thesecond encapsulating item 44 are swallowed. Thereby it is possible to easily swallow the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82. - The second effect will now be explained in detail. As mentioned above, the
first encapsulating item 42 and thesecond encapsulating item 44 enter the mouth of thepatient 200 while being enclosed in the swallowing-aid substance 40. Thereby the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82, which are the content of thefirst encapsulating item 42 and thesecond encapsulating item 44, are doubly enclosed by the swallowing-aid substance 40 and by thefirst encapsulating item 42 and second encapsulatingitem 44. Even if the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 are drugs, the probability that the tongue of thepatient 200 senses the bitterness thereof is low because the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 are doubly enclosed. As a result, the bitter taste of the drugs is suppressed. - The third effect will now be explained in detail. As mentioned above, the first
pharmaceutical composition 80 and the secondpharmaceutical composition 82 are doubly enclosed by the swallowing-aid substance 40 and by thefirst encapsulating item 42 and thesecond encapsulating item 44. This reduces the probability that the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 scatter in the mouth of thepatient 200. As a result, it is possible to suppress the scattering of the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 in the mouth. - The fourth effect will now be explained in detail. The first
pharmaceutical composition 80 and the secondpharmaceutical composition 82 are chemical substances. When chemical substances come into contact with each other, chemical reactions occur in many cases. Due to the occurrence of chemical reactions, the effect of the pharmaceutical composition as a drug is lost. For this reason, it is not possible to preserve a plurality of pharmaceutical compositions in a mixed state in many cases. If the pharmaceutical compositions are to be preserved in a mixed state, it is necessary to research in advance whether the chemical substances lose their effects. Thepharmaceutical composition container 10 of this embodiment is equipped with a plurality of spaces. Storing one type of pharmaceutical composition in each of those spaces is substantially identical with separately preserving a plurality of pharmaceutical compositions. This is the reason why concerns regarding the stability of the pharmaceutical composition are unnecessary when thepharmaceutical composition container 10 of this embodiment is used. Since concerns regarding the stability of the pharmaceutical composition are unnecessary, the advance research on whether the pharmacological effects of the plurality of pharmaceutical compositions are lost also becomes unnecessary. - The fifth effect will now be explained in detail. As the swallowing-
aid substance 40, thefirst encapsulating item 42 and thesecond encapsulating item 44 are swallowed after the swallowing-aid substance 40 is sequentially guided to the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36, the activity of the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 per se will not have a significant effect on the difficulty or easiness of swallowing any more. Thereby it is possible to let patients with swallowing difficulties ingest solids of various types. - The sixth effect will now be explained in detail. Before the
pharmaceutical composition container 10 is used, the portion of the container body that forms theapertured space 38 is covered by thecover 22. This reduces the frequency at which bacteria etc. adhere to the portion of thecontainer body 20 that forms theapertured space 38. The frequency at which bacteria etc. adhere is reduced particularly in comparison with the case where the portion of thecontainer body 20 which comes into contact with the mouth is broken to form the aperture. In the case where the portion of thecontainer body 20 which comes into contact with the mouth is broken to form the aperture, it is necessary to touch that portion with a tool or hand when breaking that portion. At this time, it is possible that bacteria or viruses adhering to the tool or hand are adhered to that portion. In the case of thepharmaceutical composition container 10 of this embodiment, the swallowing-aid substance 40, thefirst encapsulating item 42 and thesecond encapsulating item 44 can be swallowed upon breaking the firstweak seal 140 to fourthweak seal 146; therefore it is not necessary to touch, with a tool or hand, the portion of thecontainer body 20 which comes into contact with the mouth and thus the probability that bacteria or viruses adhere thereto is reduced. As a result, it is possible to improve the cleanliness during the ingestion of the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82. - The seventh effect will now be explained in detail. The end of the first
pharmaceutical composition chamber 34 on the side of the secondpharmaceutical composition chamber 36 becomes narrower towards the secondpharmaceutical composition chamber 36, and thefirst encapsulating item 42 is stored in the firstpharmaceutical composition chamber 34; therefore it is possible to smoothly push out thefirst encapsulating item 42 by means of the swallowing-aid substance 40. The end of the secondpharmaceutical composition chamber 36 on the side of theapertured space 38 becomes narrower towards theapertured space 38, and thesecond encapsulating item 44 is stored in the secondpharmaceutical composition chamber 36; therefore this second encapsulatingitem 44 is also pushed out smoothly in the same way. - The eighth effect will now be explained in detail. When the swallowing-
aid substance 40, thefirst encapsulating item 42 and thesecond encapsulating item 44 are pushed out of theaperture 60, the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 therein are pushed out at the same time. This significantly reduces the residual quantity of the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 in the firstpharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 as compared to the case where the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 are not inside thefirst encapsulating item 42 and thesecond encapsulating item 44. Moreover, thefirst encapsulating item 42 and thesecond encapsulating item 44 of this embodiment are tightly sealed. Since thefirst encapsulating item 42 and thesecond encapsulating item 44 are tightly sealed, the probability that the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 leak from thefirst encapsulating item 42 and thesecond encapsulating item 44 is extremely low. Since this probability is extremely low, it is possible to reduce the residual quantity of the firstpharmaceutical composition 80 and the secondpharmaceutical composition 82 remaining inside the pharmaceutical composition container 10 (actually, it is possible to reduce the residual quantity close to zero). - The following explains the
pharmaceutical composition container 210 of the embodiment 2 of this invention. Note that items which are identical with those explained in the embodiment 1 are given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated. -
FIG. 6 is a partial cross section of thepharmaceutical composition container 210 of this embodiment. The configuration of thepharmaceutical composition container 210 of this embodiment will be explained while referring toFIG. 6 . Thepharmaceutical composition container 210 of this embodiment is equipped with acontainer body 220 and acover 222. Thecontainer body 220 is formed by onelaminated member 50 that is folded and has the outer periphery adhered together. Thecover 222 is formed from alaminated member 50 same as thecontainer body 220. Thecover 222 is integrated with thecontainer body 220. InFIG. 6 , the hatched portion at the left end of thepharmaceutical composition container 210 shows a cross section of thelaminated member 50. - The
container body 220 comprises a swallowing-aid substance chamber 230, apharmaceutical composition chamber 232 and anapertured space 234. The swallowing-aid substance chamber 230 and thepharmaceutical composition chamber 232 are so formed as to maintain air tightness with respect to the external space around thepharmaceutical composition container 210. - A swallowing-
aid substance 40 is stored inside the swallowing-aid substance chamber 230. Afirst encapsulating item 42 is stored inside thepharmaceutical composition chamber 232. Afirst pharmaceutical composition 80 is encapsulated inside thefirst encapsulating item 42. Further, theapertured space 234 is an empty chamber until the firstweak seal 240 and the secondweak seal 242, which will be explained later, are broken. - Note that, if necessary, a gas which does not have any effect on the first
pharmaceutical composition 80 or the swallowing-aid substance 40 is filled into the swallowing-aid substance chamber 230 and thepharmaceutical composition chamber 232. - The portion between the swallowing-
aid substance chamber 230 and thepharmaceutical composition chamber 232 is partitioned by a firstweak seal 240. The portion between thepharmaceutical composition chamber 232 and theapertured space 234 is partitioned by a secondweak seal 242. The firstweak seal 240 and the secondweak seal 242 are disposed in the portions corresponding to the portions between two adjoining spaces of the spaces formed by thecontainer body 220. - The strength of the first
weak seal 240 and the secondweak seal 242 is weaker than the strength of the bottomstrong seal 260 and the sidestrong seal 262. The bottomstrong seal 260 is the portion on the boundary between thecontainer body 220 and thecover 222 where the surfaces of thelaminated members 50 are adhered to each other. The sidestrong seal 262 is the portion where the surfaces of thelaminated member 50 are adhered to each other excluding the firstweak seal 240, the secondweak seal 242 and the bottomstrong seal 260. In the case of this embodiment, the strength of the firstweak seal 240 and the secondweak seal 242 is such that the firstweak seal 240 and the secondweak seal 242 can be broken by the pressure of the swallowing-aid substance 40, same as in the embodiment 1. Further, also same as in the embodiment 1, the specific method for breaking the firstweak seal 240 and the secondweak seal 242 is not limited to breaking by means of the pressure from the swallowing-aid substance 40. - The configuration of the first
weak seal 240 and the secondweak seal 242 is the same as the configuration of the firstweak seal 140 to fourthweak seal 146 of the embodiment 1. Further, the configuration of the bottomstrong seal 260 and the sidestrong seal 262 is the same as that of the bottomstrong seal 160 and the sidestrong seal 162 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here. - In this embodiment, the two corners of the portion corresponding to the tip of the
apertured space 234 of thecontainer body 220 are folded over. However, to make the configuration of thepharmaceutical composition container 210 easy to grasp,FIG. 6 shows a state where only one of those corners is folded over. Those two corners are folded over in order to facilitate the insertion of the portion corresponding to the tip of theapertured space 234 into thecover 222 in the same way as in the embodiment 1. Accordingly, if there is no particular problem, only one of those two corners may be folded over. - The production method and usage method of the
pharmaceutical composition container 210 of this embodiment is the same as the production method and usage method of thepharmaceutical composition container 10 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here. - In this way, the
pharmaceutical composition container 210 of this embodiment produces the following six effects. The first effect is that it is possible to easily swallow the firstpharmaceutical composition 80. The second effect is that, if the firstpharmaceutical composition 80 has a bitter taste, that bitter taste is suppressed. The third effect is that it is possible to suppress the scattering of the firstpharmaceutical composition 80 in the mouth. The fourth effect is that it is possible to let patients with swallowing difficulties ingest solids of various types. The fifth effect is that it is possible to improve the cleanliness during the ingestion of the firstpharmaceutical composition 80. The reasons why those effects are produced are the same as in the case of the embodiment 1, and therefore a detailed explanation thereof will not be repeated here. The sixth effect is that it is possible to reduce the residual quantity of thepharmaceutical composition 80 inside the pharmaceutical composition container 210 (in this embodiment, it is possible to reduce the residual quantity close to zero). - The following explains the
pharmaceutical composition container 310 of the embodiment 3 of this invention. Note that items which are identical with those explained in the embodiments 1 and 2 are given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated. -
FIG. 7 is a partial cross section of thepharmaceutical composition container 310 of this embodiment. The configuration of thepharmaceutical composition container 310 of this embodiment will be explained while referring toFIG. 7 . Thepharmaceutical composition container 310 of this embodiment is equipped with acontainer body 320 and acover 322. Thecontainer body 220 is formed by melt-bonding the outer edge of twolaminated members 50. Thecover 222 is separate from thecontainer body 220. The sheet forming thecover 222 in this embodiment is formed of a known resin. - The
container body 320 comprises abag storage chamber 330, a firstpharmaceutical composition chamber 334, a secondpharmaceutical composition chamber 336 and anapertured space 338. Thebag storage chamber 330, the firstpharmaceutical composition chamber 334 and the secondpharmaceutical composition chamber 336 are so formed as to maintain air tightness with respect to the external space around thecontainer body 320. - An aid-
substance storage bag 340 is stored inside thebag storage chamber 330. The aid-substance storage bag 340 is fixed inside thebag storage chamber 330 by means of the circumferentialstrong seal 462, which will be explained later. - A swallowing-
aid substance 40 is stored inside the aid-substance storage bag 340. On the aid-substance storage bag 340, the strength of the end facing the firstweak seal 440, which will be explained later, has the same structure as that of the firstweak seal 140 to fourthweak seal 146 of the embodiment 1. Accordingly, this portion can be broken by the pressure of the swallowing-aid substance 40. The swallowing-aid substance 40 is sterilized together with the aid-substance storage bag 340 and then sandwiched in thecontainer body 320. After that, the circumferentialstrong seal 462 is formed, whereby the aid-substance storage bag 340 is adhered inside the circumferentialstrong seal 462. - A
first encapsulating item 42 is stored inside the firstpharmaceutical composition chamber 334. Afirst pharmaceutical composition 80 is encapsulated inside thefirst encapsulating item 42. Apowder drug 344 is stored inside the secondpharmaceutical composition chamber 336. Theapertured space 338 in this embodiment is an empty chamber until the firstweak seal 440 to thirdweak seal 444 are broken. - The portion between the
bag storage chamber 330 and the firstpharmaceutical composition chamber 334 is partitioned by a firstweak seal 440. The portion between the firstpharmaceutical composition chamber 334 and the secondpharmaceutical composition chamber 336 is partitioned by a secondweak seal 442. The portion between the secondpharmaceutical composition chamber 336 and theapertured space 338 is partitioned by a thirdweak seal 444. The firstweak seal 440, the secondweak seal 442 and the third weak seal 444 (these are referred to as “firstweak seal 440 to thirdweak seal 444”) are disposed in the portions between two adjoining spaces of the spaces formed by thecontainer body 320. - The strength of the first
weak seal 440 to thirdweak seal 444 is weaker than the strength of the circumferentialstrong seal 462. The circumferentialstrong seal 462 is the portion where the edge of thecontainer body 320 is adhered. In the case of this embodiment, the strength of the firstweak seal 440 to thirdweak seal 444 is such that the firstweak seal 440 to thirdweak seal 444 can be broken by the pressure of the swallowing-aid substance 40, same as in the embodiments 1 and 2. Same as in the embodiments 1 and 2, the specific method for breaking the firstweak seal 440 to thirdweak seal 444 is not limited to breaking by means of the pressure from the swallowing-aid substance 40. - The configuration of the first
weak seal 440 to thirdweak seal 444 is the same as the configuration of the firstweak seal 140 to fourthweak seal 146 of the embodiment 1. Further, the configuration of the circumferentialstrong seal 462 is the same as that of the sidestrong seal 162 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here. - The production procedure for the
pharmaceutical composition container 310 of this embodiment will now be explained. In the first step, two sheets of alaminated member 50 are superposed on each other and the outer edge thereof is heated. However, no heat is applied to the portion where the aid-substance storage bag 340 is to be sandwiched. In the second step, the periphery of the firstweak seal 440 on thelaminated member 50 is heated. Thereby, the firstweak seal 440 is formed. In the third step, thefirst encapsulating item 42 is inserted between thelaminated members 50. In the fourth step, the periphery of the portion between the firstpharmaceutical composition chamber 334 and the secondpharmaceutical composition chamber 336 on thelaminated member 50 is heated. Thereby the secondweak seal 442 is formed. In the fifth step, thepowder drug 344 is filled between thelaminated member 50. In the sixth step, the periphery of the portion between the secondpharmaceutical composition chamber 336 and theapertured space 338 on thelaminated member 50 is heated. Thereby the thirdweak seal 444 is formed. In the seventh step, the aid-substance storage bag 340 is inserted between thelaminated member 50. At this time, first, the portion of the firstweak seal 440 on thecontainer body 320 is folded over, and thebag storage chamber 330 is oriented upwards. When thebag storage chamber 330 is oriented upwards, the aperture on thebag storage chamber 330 is opened widely and the aid-substance storage bag 340 is inserted thereinto. In the eighth step, the portion on the outer edge of thecontainer body 320 where the aid-substance storage bag 340 is sandwiched is heated. In the ninth step, thecover 322 is placed over the outer side of the portion of thecontainer body 320 which forms theapertured space 338. Thepharmaceutical composition container 310 which is completed through these steps is packed into a carton box which is not shown in the drawings, and distributed. - The usage method of the
pharmaceutical composition container 310 of this embodiment is the same as the usage method of thepharmaceutical composition container 10 of the embodiment 1 except for the fact that first thecover 322 is removed from the portion of thecontainer body 320 which forms theapertured space 338. Accordingly, a detailed explanation thereof will not be repeated here. - In this way, the
pharmaceutical composition container 310 of this embodiment produces the following five effects. The first effect is that it is possible to easily swallow a granular drug or anotherpharmaceutical composition 80. The second effect is that, if the firstpharmaceutical composition 80 has a bitter taste, that bitter taste is suppressed. The third effect is that concerns regarding the stability of the drug become unnecessary. The fourth effect is that it is possible to improve the cleanliness during the ingestion of the firstpharmaceutical composition 80 and thepowder drug 344. The fifth effect is that it is possible to reduce the residual quantity of thepharmaceutical compositions - The following explains the
pharmaceutical composition container 510 of the embodiment 4 of this invention. Note that items which are identical with those explained in the embodiments 1 and 2 are given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated. -
FIG. 8 is a partial cross section of thepharmaceutical composition container 510 of this embodiment. The configuration of thepharmaceutical composition container 510 of this embodiment will be explained while referring toFIG. 8 . Thepharmaceutical composition container 510 of this embodiment is equipped with acontainer body 520 and acover 522, which is integrated with thecontainer body 520. Same as in the embodiment 2, thecontainer body 520 and thecover 522 of this embodiment are formed by double-folding onelaminated member 50 and adhering the outer peripheries thereof. InFIG. 8 , the hatched portion at the right end of thepharmaceutical composition container 510 shows a cross section of thelaminated member 50. - The
container body 520 is equipped with a swallowing-aid substance chamber 530, anintermediate chamber 532, a firstpharmaceutical composition chamber 534, a secondpharmaceutical composition chamber 536 and anapertured space 538. The swallowing-aid substance chamber 530, theintermediate chamber 532, the firstpharmaceutical composition chamber 534 and the secondpharmaceutical composition chamber 536 are so formed as to maintain air tightness with respect to the external space around thepharmaceutical composition container 510. Thecover 522 can cover the outside of the portion of thecontainer body 520 which forms theapertured space 538. - A third
pharmaceutical composition 84 is stored inside the firstpharmaceutical composition chamber 534. The thirdpharmaceutical composition 84 is a medicinal powder. A fourthpharmaceutical composition 86 is stored inside the secondpharmaceutical composition chamber 536. The fourthpharmaceutical composition 86 is a medicinal powder of a type that is different to that of the thirdpharmaceutical composition 84. Naturally, it is needless to say that the firstpharmaceutical composition chamber 534 and the secondpharmaceutical composition chamber 536 may also store a granular drug or another substance. - Note that, if necessary, a gas which does not have any effect on the third
pharmaceutical composition 84, the fourthpharmaceutical composition 86 and the swallowing-aid substance 40, is filled into the swallowing-aid substance chamber 530, the firstpharmaceutical composition chamber 534 and the secondpharmaceutical composition chamber 536. - The
intermediate chamber 532 and theapertured space 538 are empty chambers until the firstweak seal 640 to fourthweak seal 646 are broken. Theapertured space 538 comprises an aperture. - The portion between the swallowing-
aid substance chamber 530 and theintermediate chamber 532 is partitioned by a firstweak seal 640. The portion between theintermediate chamber 532 and the firstpharmaceutical composition chamber 534 is partitioned by a secondweak seal 642. The portion between the firstpharmaceutical composition chamber 534 and the secondpharmaceutical composition chamber 536 is partitioned by a thirdweak seal 644. The portion between the secondpharmaceutical composition chamber 536 and theapertured space 538 is partitioned by a fourthweak seal 646. - The strength of the first
weak seal 640 to fourthweak seal 646 is weaker than the strength of the bottomstrong seal 660 and the sidestrong seal 662. In the case of this embodiment, the strength of the firstweak seal 640 to fourthweak seal 646 is such that the firstweak seal 640 to fourthweak seal 646 can be broken by the pressure of the swallowing-aid substance 40 (this pressure being caused by the application of force by an adult person from the outside of the swallowing-aid substance chamber 30). The specific method for breaking the portion between the swallowing-aid substance chamber 530 and theintermediate chamber 532, the portion between theintermediate chamber 532 and the firstpharmaceutical composition chamber 534, the portion between the firstpharmaceutical composition chamber 534 and the secondpharmaceutical composition chamber 536 and the portion between the secondpharmaceutical composition chamber 536 and theapertured space 538 is not limited to breaking by means of pressure from the swallowing-aid substance 40. - The usage method of the
pharmaceutical composition container 510 of this embodiment is the same as the usage method of thepharmaceutical composition container 10 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here. - In this way, the
pharmaceutical composition container 510 of this embodiment produces the following four effects. The first effect is that it is possible to easily swallow a medicinal powder or another pharmaceutical composition. The second effect is that concerns regarding the stability of the drug become unnecessary. The third effect is that, because a step is provided on the portion of the sidestrong seal 662 that is adjacent to the thirdweak seal 644, the tip of thepharmaceutical composition container 510 is prevented from entering the mouth of thepatient 200 too far during the ingestion of a pharmaceutical composition using thepharmaceutical composition container 510 of this embodiment. The fourth effect is that it is possible to improve the cleanliness during the ingestion of the thirdpharmaceutical composition 84 and the fourthpharmaceutical composition 86. - The following explains the
pharmaceutical composition container 710 of the embodiment 5 of this invention. Note that items which are identical with those explained in the embodiments 1 to 4 were given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated. -
FIG. 9 is a partial cross section of thepharmaceutical composition container 710 of this embodiment. Thepharmaceutical composition container 710 of this embodiment is equipped with acontainer body 820 and acover 822, which is integrated with thecontainer body 820. Same as in the embodiments 1 and 3, thepharmaceutical composition container 710 is formed by adhering twolaminated members 50 to each other. - The
container body 820 comprises a swallowing-aid substance chamber 830, a firstpharmaceutical composition chamber 834 and anapertured space 838. The swallowing-aid substance chamber 830 and the firstpharmaceutical composition chamber 834 are so formed as to maintain air tightness with respect to the external space around thepharmaceutical composition container 710. - A third
pharmaceutical composition 84 is stored inside the firstpharmaceutical composition chamber 834. It is needless to say that the firstpharmaceutical composition chamber 834 may also store a granular drug or another substance. - If necessary, a gas which does not have any effect on the third
pharmaceutical composition 84 and the swallowing-aid substance 40 is filled into the swallowing-aid substance chamber 830 and the firstpharmaceutical composition chamber 834. - The
apertured space 838 is an empty chamber until the firstweak seal 840 and the secondweak seal 842 are broken. Theapertured space 838 comprises an aperture. - The portion between the swallowing-
aid substance chamber 830 and the firstpharmaceutical composition chamber 834 is partitioned by a firstweak seal 840. The portion between the firstpharmaceutical composition chamber 834 and theapertured space 838 is partitioned by a secondweak seal 842. - The strength of the first
weak seal 840 and the secondweak seal 842 is weaker than the strength of the bottomstrong seal 860 and the sidestrong seal 862. - The usage method of the
pharmaceutical composition container 710 of this embodiment is the same as the usage method of thepharmaceutical composition container 10 of the embodiment 1. Accordingly, a detailed explanation thereof will not be repeated here. - In this way, the
pharmaceutical composition container 710 of this embodiment produces the following three effects. The first effect is that it is possible to easily swallow a medicinal powder or another pharmaceutical composition. The second effect is that concerns regarding the stability of the drug become unnecessary. The third effect is that it is possible to improve the cleanliness during the ingestion of the thirdpharmaceutical composition 84. - The following explains embodiment 6 of this invention. Note that items which are identical with those explained in the embodiment 1 are given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated.
-
FIG. 10 is a partial cross section of thepharmaceutical composition container 260 of this embodiment. Thepharmaceutical composition container 260 of this embodiment is formed by double-folding one sheet made of a synthetic resin (low-density polyethylene, PET (polyethylene terephthalate) or another resin that is soft so as to be foldable and is heat-sealable, like composite resin), adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion. - The portion where the ends of the sheet are adhered to each other is the side
strong seal 270. The inside of thepharmaceutical composition container 260 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a firstweak seal 300, a secondweak seal 302 and a thirdweak seal 304. The firstweak seal 300 comprises afirst zone 311, anintermediate chamber 312 and asecond zone 314. - One of the spaces inside the
pharmaceutical composition container 260 is the swallowing-aid substance chamber 280. A swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 280. When force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 260, thefirst zone 311 of the firstweak seal 300 easily opens by means of the pressure received from the swallowing-aid substance 40. When thefirst zone 311 opens, the swallowing-aid substance 40 is pushed out into theintermediate chamber 312. Thereafter, thesecond zone 314, the secondweak seal 302 and the thirdweak seal 304 sequentially open in the same way. This can be realized because the strength of the firstweak seal 300, the secondweak seal 302 and the thirdweak seal 304 is weak compared to that of the sidestrong seal 270. - In one type of the spaces inside the
pharmaceutical composition container 260, the firstpharmaceutical composition chamber 282 and the secondpharmaceutical composition chamber 284 exist. The firstpharmaceutical composition chamber 282 and the secondpharmaceutical composition chamber 284 store afirst encapsulating item 212 or asecond encapsulating item 213. The pharmaceutical composition encapsulated by thefirst encapsulating item 212 stored in the firstpharmaceutical composition chamber 282 and the pharmaceutical composition encapsulated by thesecond encapsulating item 213 stored in the secondpharmaceutical composition chamber 284 are of different types. - One of the spaces inside the
pharmaceutical composition container 260 also contains anapertured space 286. Theapertured space 286 is provided on one end of thepharmaceutical composition container 260 and serves as the chute (in other words, the device for dropping thefirst encapsulating item 212 and thesecond encapsulating item 213 into the mouth of the patient) for the ingestion of thefirst encapsulating item 212 and thesecond encapsulating item 213. - Of the two ends of the
pharmaceutical composition container 260, the end on the opposite side of the end on which theapertured space 286 is provided, is thecover 288. The boundary between the swallowing-aid substance chamber 280 and thecover 288 is the bottomstrong seal 272. The strength of the bottomstrong seal 272 is the same as that of the sidestrong seal 270; therefore the bottomstrong seal 272 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 260. Note that, in the explanation of thepharmaceutical composition container 260 of this embodiment, the portion which is more to the side of the secondpharmaceutical composition chamber 284 than thecover 288 is referred to as the “container body.” -
FIG. 11 is an overview of the portion of thepharmaceutical composition container 260 of this embodiment which corresponds to the rear surface when viewed as shown inFIG. 10 . As is obvious fromFIG. 11 , alabel 262 is adhered to thepharmaceutical composition container 260 of this embodiment. - <Features Unique to this Embodiment>
- The features unique to the
pharmaceutical composition container 260 of this embodiment as compared to the pharmaceutical composition containers of the other embodiments are that: thecover 288 is disposed on one end and acover insert portion 321 which is inserted into thiscover 288 is disposed on the other end; the width of thepharmaceutical composition container 260 is larger on thebase 331 of the portion which is inserted into the cover 238; the bottomstrong seal 272 and a portion of the secondweak seal 302 or a portion of the thirdweak seal 304 are folded over to insert the tip of thecover insert portion 321 into thecover 288, and thebase 331 is on the outside of thecover 288.FIG. 12 shows the state where thecover insert portion 321 is inserted into the cover 238 and thebase 331 is on the outside of the cover 238. As is obvious fromFIG. 12 , the portion of thebase 331 is depressed; therefore it is possible to easily to pull out thecover insert portion 321 by inserting a finger thereinto.FIG. 13 is a view of the portion which corresponds to the rear surface when viewed as shown inFIG. 12 , in the state shown inFIG. 12 . The major part of the rear surface of thepharmaceutical composition container 260 is occupied by thelabel 262. - When using the
pharmaceutical composition 260 of this embodiment, a finger is engaged with theabovementioned base 331 and the abovementionedcover insert portion 321 is pulled out of the cover 238 in this state. When thecover insert portion 321 is pulled out, thecover insert portion 321 is placed into the mouth of the patient. The subsequent usage method is the same as in the other embodiments or alternative embodiments thereof. - With the
pharmaceutical composition container 260 of this embodiment, thecover insert portion 321 can easily be pulled out because a finger can be engaged with thebase 331 of thecover insert portion 321. - Further, the
pharmaceutical composition container 260 of this embodiment produces the same effects like that of the embodiment 1. - The following explains embodiment 7 of this invention. Note that items which are identical with those explained in the embodiment 1 are given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated.
-
FIG. 14 is a partial cross section of thepharmaceutical composition container 400 of this embodiment. Same as in the embodiment 6, thepharmaceutical composition container 400 of this embodiment is formed by double-folding one sheet made of a synthetic resin, adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion. - The portion where the ends of the sheet were adhered to each other is the side
strong seal 410. The inside of thepharmaceutical composition container 400 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a firstweak seal 441, a secondweak seal 443 and a thirdweak seal 445. The firstweak seal 441 comprises afirst zone 450, anintermediate chamber 452 and asecond zone 454. - One of these spaces is the swallowing-
aid substance chamber 420. A swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 420. When force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 400, thefirst zone 450 and thesecond zone 454 sequentially open in the same way as the firstweak seal 300, the secondweak seal 302 and the thirdweak seal 304 in the embodiment 6. The reason why thefirst zone 450 and thesecond zone 454 open in this way is the same as that in the embodiment 6. - In one type of the spaces inside the
pharmaceutical composition container 400, the firstpharmaceutical composition chamber 422 and the secondpharmaceutical composition chamber 424 exist. The firstpharmaceutical composition chamber 422 and the secondpharmaceutical composition chamber 424 store afirst encapsulating item 212 or asecond encapsulating item 213. The pharmaceutical composition encapsulated by thefirst encapsulating item 212 stored in the firstpharmaceutical composition chamber 422 and the pharmaceutical composition encapsulated by thesecond encapsulating item 213 stored in the secondpharmaceutical composition chamber 424 are of different types. - One of these spaces also contains an
apertured space 426. Same as theapertured space 286 of the embodiment 6, theapertured space 426 serves as the chute for the ingestion of thefirst encapsulating item 212 and thesecond encapsulating item 213. - Of the two ends of the
pharmaceutical composition container 400, the end on the opposite side of the end on which theapertured space 426 is provided, is thecover 428. The boundary between the swallowing-aid substance chamber 420 and the cover 478 is the bottomstrong seal 412. The strength of the bottomstrong seal 412 is the same as that of the sidestrong seal 410; therefore the bottomstrong seal 412 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 400. - <Features Unique to this Embodiment>
- The features unique to the
pharmaceutical composition container 400 of this embodiment as compared with the pharmaceutical composition containers of the other embodiments are that: the cover 478 is disposed on one end; the bottomstrong seal 412 and the base of the portion where theapertured space 426 is disposed are folded over to insert the portion where theapertured space 426 is disposed into the cover 478; thetip 480 of the portion where theapertured space 426 is disposed is round; and a part of the edge 482 of the cover 478 is cut out. Note that, in the explanation of thepharmaceutical composition container 400 of this embodiment, the portion which is more to the side of the secondpharmaceutical composition chamber 424 than the cover 478 is referred to as the “container body.” - When using the
pharmaceutical composition 351 of this embodiment, the one of the two ends of thepharmaceutical composition container 400 on which theapertured space 426 is disposed is pulled out of the cover 478. The subsequent usage method is the same as in the other embodiments. - During the production of the
pharmaceutical composition container 400 of this embodiment, thepharmaceutical composition container 400 is folded over in such a manner that the portion where theapertured space 426 is disposed and the cut-out edge 482 of the cover 478 face each other.FIG. 15 shows the state in whichpharmaceutical composition container 400 is folded over during production. After thepharmaceutical composition container 400 is folded over, the portion where theapertured space 426 is disposed is inserted into the cover 478. At this time, thetip 480 of the portion where theapertured space 426 is disposed gets caught at any position of the cut-out edge 482 of the cover 478 and opens the mouth of the cover 478. Since the mouth of the cover 478 is opened, thetip 480 smoothly enters the inside of the cover 478.FIG. 16 shows thepharmaceutical composition container 400 after the portion where theapertured space 426 is disposed is inserted into the cover 478. - Further, the
pharmaceutical composition container 400 of this embodiment produces the same effects like that of the embodiment 1. - The following explains embodiment 8 of this invention. Note that items which are identical with those explained in the embodiment 1 are given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated.
-
FIG. 17 is a partial cross section of thepharmaceutical composition container 500 of this embodiment. Same as in the embodiment 6, thepharmaceutical composition container 500 of this embodiment is formed by double-folding one sheet made of a synthetic resin, adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion. - The portion where the ends of the sheet are adhered to each other is the side
strong seal 511. The inside of thepharmaceutical composition container 500 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a firstweak seal 540, a second weak seal 542 and a thirdweak seal 544. The firstweak seal 540 comprises afirst zone 550, anintermediate chamber 552 and asecond zone 554. - One of the spaces inside the
pharmaceutical composition container 500 is the swallowing-aid substance chamber 521. A swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 521. When force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 500, thefirst zone 550 and thesecond zone 554 sequentially open in the same way as the firstweak seal 300, the secondweak seal 302 and the thirdweak seal 304 in the embodiment 6. The reason why thefirst zone 550 and thesecond zone 554 open in this way is the same as that in the embodiment 6. - In one type of the spaces inside the
pharmaceutical composition container 500, the firstpharmaceutical composition chamber 523 and the secondpharmaceutical composition chamber 524 exist. The firstpharmaceutical composition chamber 523 and the secondpharmaceutical composition chamber 524 store afirst encapsulating item 212 or asecond encapsulating item 213. The pharmaceutical composition encapsulated by thefirst encapsulating item 212 stored in the firstpharmaceutical composition chamber 523 and the pharmaceutical composition encapsulated by thesecond encapsulating item 213 stored in the secondpharmaceutical composition chamber 524 are of different types. - One of these spaces also contains an
apertured space 526. Same as theapertured space 286 of the embodiment 6, theapertured space 526 serves as the chute for the ingestion of thefirst encapsulating item 212 and thesecond encapsulating item 213. - Of the two ends of the
pharmaceutical composition container 500, the end on the opposite side of the end on which theapertured space 526 is provided, is thecover 528. The boundary between the swallowing-aid substance chamber 521 and thecover 528 is the bottomstrong seal 512. The strength of the bottomstrong seal 512 is the same as that of the sidestrong seal 511; therefore the bottomstrong seal 512 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 500. Note that, in the explanation of thepharmaceutical composition container 500 of this embodiment, the portion which is more to the side of the secondpharmaceutical composition chamber 524 than thecover 528 is referred to as the “container body.” - <Features Unique to this Embodiment>
-
FIG. 18 is a partial cross section showing one end of thepharmaceutical composition container 500 during the production thereof.FIG. 19 is a perspective view showing one end of thepharmaceutical composition container 500 during the production thereof. The features unique to thepharmaceutical composition container 500 as compared to the pharmaceutical composition containers of the other embodiments will be explained while referring toFIG. 18 andFIG. 19 . The features thereof are that: the bottomstrong seal 512 and the base of the portion where theapertured space 526 is disposed are folded over to insert the portion where theapertured space 526 is disposed into thecover 528; and a melt-bonding margin 514 is disposed on thetip portion 516 which is inserted into thecover 528 on the sidestrong seal 511. This melt-bonding margin 514 is folded back like shown inFIG. 19 and melt-bonded to thetip portion 516. - The usage method of the
pharmaceutical composition container 500 of this embodiment is the same as that of the embodiment 7. - Even if there are burrs at the end of the side
strong seal 511, those burrs do not easily touch the inside of the mouth of the patient because thepharmaceutical composition container 500 of this embodiment has a structure like that mentioned above. Since the burrs do not easily touch the inside of the mouth, the mouth of the patient is not easily scratched. - Further, the
pharmaceutical composition container 500 of this embodiment produces the same effects like that of the embodiment 1. - The following explains embodiment 9 of this invention. Note that items which are identical with those explained in the embodiment 1 are given identical reference numerals. In this embodiment, the detailed explanation thereof will not be repeated.
-
FIG. 20 is a partial cross section of thepharmaceutical composition container 351 of this embodiment. Same as in the embodiment 6, thepharmaceutical composition container 351 of this embodiment is formed by double-folding one sheet made of a synthetic resin, adhering the ends of the double-folded sheet to each other and aligning the outer shape by cutting the adhered portion. - The portion where the ends of the sheet are adhered to each other is the side
strong seal 361. The inside of thepharmaceutical composition container 351 is provided with a plurality of spaces. The portions between the plurality of spaces are sealed by a firstweak seal 390, a secondweak seal 392 and apredetermined aperture part 394. The firstweak seal 390 comprises afirst zone 401, anintermediate chamber 403 and asecond zone 405. - One of the spaces inside the
pharmaceutical composition container 351 is the swallowing-aid substance chamber 370. A swallowing-aid substance 40 is stored inside the swallowing-aid substance chamber 370. When force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 351, thefirst zone 401 and thesecond zone 405 sequentially open in the same way as the firstweak seal 300, the secondweak seal 302 and the thirdweak seal 304 in the embodiment 6. The reason why thefirst zone 401 and thesecond zone 405 open in this way is the same as that in the embodiment 6. - In one type of the spaces inside the
pharmaceutical composition container 351, the firstpharmaceutical composition chamber 372 and the secondpharmaceutical composition chamber 374 exist. Afirst encapsulating item 212 is stored in the firstpharmaceutical composition chamber 372. A knowntablet 352 is stored in the secondpharmaceutical composition chamber 374. - Of the two ends of the
pharmaceutical composition container 351, the end on the opposite side of the end on which thepredetermined aperture part 394 is provided, is thecover 378. The boundary between the swallowing-aid substance chamber 370 and thecover 378 is the bottomstrong seal 362. The strength of the bottomstrong seal 362 is the same as that of the sidestrong seal 361; therefore the bottomstrong seal 362 is not broken even when force is applied to the swallowing-aid substance 40 from the outside of thepharmaceutical composition container 351. Note that, in the explanation of thepharmaceutical composition container 351 of this embodiment, the portion which is more to the side of the secondpharmaceutical composition chamber 374 than thecover 378 is referred to as the “container body.” - When the production of the
pharmaceutical composition container 351 of this embodiment is finished, the portion where thepredetermined aperture part 394 is provided is so inserted into thecover 378 as to allow being pulled out.FIG. 21 is an external view of thepharmaceutical composition container 351 at this time. - <Features Unique to this Embodiment>
- The features unique to the
pharmaceutical composition container 351 as compared to the pharmaceutical composition containers of the other embodiments are that: theportion 354 which is inserted into thecover 378 is provided with apredetermined aperture part 394; and the seal strength of thatpredetermined aperture part 394 is weaker than the seal strength of the sidestrong seal 361. - The usage method of the
pharmaceutical composition container 351 of this embodiment is the same as that of the embodiment 7. - On the
pharmaceutical composition container 351 of this embodiment, the seal strength of thepredetermined aperture part 394 is weaker than the seal strength of the sidestrong seal 361. For this reason, thepredetermined aperture part 394 opens when theportion 354 where thepredetermined aperture part 394 is disposed is put into the mouth of the patient and thepharmaceutical composition container 351 is squeezed. Thereby the aperture is formed. The aperture interconnects the outside of thepharmaceutical composition container 351 with the spaces. As a result, it is possible to put thefirst encapsulating item 212 and thetablet 352 into the mouth of the patient without touching the portion that initially was inserted into thecover 378 with the hand. - Further, the
pharmaceutical composition container 351 of this embodiment produces the same effects like that of the embodiment 1. - The abovementioned
pharmaceutical composition containers container body container bodies pharmaceutical composition containers - For example, the form of the
first encapsulating item 42 and thesecond encapsulating item 44 is not limited to the above-mentioned form. For example, the shape thereof may be rectangular. Further, as an alternative to thefirst encapsulating item 42 and thesecond encapsulating item 44, publicly known capsules may also be stored. - Moreover, the shape of the spaces comprised in the
container bodies pharmaceutical composition chamber 34 and the secondpharmaceutical composition chamber 36 shown inFIG. 1 have a hexagonal shape, but these chambers may also have a triangular, quadrangular, pentagonal, heptagonal or other polygonal shape, or a circular or oval shape. Moreover, the number of the spaces comprised in thecontainer bodies - In addition, a chamber of the same kind as the
intermediate chamber 32 of the embodiment 1 may also be disposed in thepharmaceutical composition container 210 of the embodiment 2, thepharmaceutical composition container 310 of the embodiment 3 or thepharmaceutical composition container 710 of the embodiment 5. Furthermore, theintermediate chamber 32 in the embodiment 1 is not a mandatory space. - Moreover, the
container body 20 of the embodiment 1 and thecontainer body 320 of the embodiment 3 are not limited to being formed by adhering two sheets to each other. Thecontainer body 220 of the embodiment 2 is not limited to being formed by adhering the outer edge of one sheet. Thecontainer body 220 of the embodiment 2 may also be formed by adhering two sheets to each other. Thecontainer body 20 of the embodiment 1 and thecontainer body 320 of the embodiment 3 may also be formed by double-folding one sheet and adhering the outer edges to each other. - Further, in the abovementioned embodiments, cases were explained where the pharmaceutical composition is a powdered or granular preparation and the swallowing-aid substance is a jelly; however, it is needless to say that the pharmaceutical composition and swallowing-aid substance applied to this invention are not limited thereto. For example, apart from a powdered or granular preparation, the pharmaceutical composition may be a tablet, a capsule or a simple block. The pharmaceutical composition does not have to be stored in the first
pharmaceutical composition chamber 34 or the secondpharmaceutical composition chamber 36 in the form of an encapsulating item. That is to say, the pharmaceutical composition does not have to be wrapped in a wafer or other wrapping material. Moreover, the item formed as the pharmaceutical composition is not limited to an item that is usually treated as a medical drug. For example, the item formed as the pharmaceutical composition may also be a food which is recognized for its effect of improving the health state. The swallowing-aid substance may be an aqueous solution, or may also be honey, custard cream, peanut butter, cheese spread or the like. However, it is preferable that the swallowing-aid substance have a fluidity of a degree that allows the swallowing-aid substance to move around the spaces provided in the container body in the environment where the pharmaceutical composition container is used. - On a side note, if it is confirmed that there is no change in nature while the medical drug is distributed or while that medical drug is preserved, the combined drug may be stored in one pharmaceutical composition chamber. The combined drug mentioned here indicates a mixture.
- If an encapsulating item is stored in the pharmaceutical composition container, it is possible to use, as the material for that encapsulating item, a wafer made of starch with a thickness of 15 μm as mentioned above, or a variety of other materials conventionally known as edible film materials. The types of these materials include polysaccharides (for example, pullulan, arabinoxylan, decomposition products of guar gum, sodium alginate, carrageenan, agar-agar, pectin, cellulose, etc.) and peptide-based substances (for example, gelatin, decomposition products of silk protein, decomposition products of casein, etc.). Those materials may be used on a standalone basis or as a combination of two or more types.
- The pharmaceutical composition container of this invention is suitable for the use as, for example, a container for the ingestion of a drug. Specifically, the pharmaceutical composition container of this invention is suitable for the use as a container for the ingestion of a drug, wherein the drug is filled into the container by a system as mentioned below. Such system is one wherein a plurality of auger filling machines are set up, a transport system and weighing system are added, the filling machines, the transport system and the weighing system are connected to a medical-drug production line and automatic operation is performed over a long time.
-
-
- 10, 210, 260, 310, 351, 400, 500, 510 and 710: pharmaceutical composition container
- 20, 220, 320, 520, 720 and 820: container body
- 22, 222, 238, 288, 378, 428, 478, 322, 522, 528 and 822: cover
- 30, 230, 370, 420, 530 and 830: swallowing-aid substance chamber
- 32 and 532: intermediate chamber
- 34, 282, 334, 372, 422, 523, 534 and 834: first pharmaceutical composition chamber
- 36, 284, 336, 374, 424, 524 and 536: second pharmaceutical composition chamber
- 38, 234, 286, 338, 426, 526, 538 and 838: apertured space
- 40: swallowing-aid substance
- 42 and 212: first encapsulating item
- 44 and 213: second encapsulating item
- 50: laminated member
- 60: aperture
- 80: first pharmaceutical composition
- 82: second pharmaceutical composition
- 84: third pharmaceutical composition
- 86: fourth pharmaceutical composition
- 100: outer skin member
- 102: intermediate member
- 104: sealing member
- 140, 240, 300, 390, 440, 441, 540, 640 and 840: first weak seal
- 142, 242, 302, 392, 442, 443, 542, 642 and 842: second weak seal
- 144, 304, 444, 445 and 544: third weak seal
- 146: fourth weak seal
- 160, 260, 272, 362, 412, 512, 660 and 860: bottom strong seal
- 162, 262, 270, 361, 410, 511, 662 and 862: side strong seal
- 200: patient
- 230, 280 and 521: swallowing-aid substance chamber
- 232: pharmaceutical composition chamber
- 262: label
- 311,401,450 and 550: first zone
- 312,403,452 and 552: intermediate chamber
- 314,405,454 and 554: second zone
- 321: cover insert portion
- 330: bag storage chamber
- 331: base
- 340: aid-substance storage bag
- 344: powder drug
- 352: tablet
- 394: predetermined aperture part
- 462: circumferential strong seal
- 480: tip
- 482: edge
- 516: tip portion
Claims (5)
1. A pharmaceutical composition container equipped with at least three spaces in a container body, wherein the aforementioned pharmaceutical composition container is further equipped with a cover, the portions between two adjoining aforementioned spaces are sealed, the aforementioned portions between two adjoining spaces open when force is applied thereto from the outside of the aforementioned pharmaceutical composition container, at least one of the aforementioned spaces is an apertured space having an aperture, a swallowing-aid substance is stored in a swallowing-aid substance chamber which is at least one of the aforementioned spaces, a pharmaceutical composition is stored in a pharmaceutical composition chamber which is at least one of the aforementioned spaces, and the portion on the aforementioned container body which forms the aforementioned apertured space is covered by the aforementioned cover.
2. The pharmaceutical composition container described in claim 1 , wherein the aforementioned cover is integrated with the aforementioned container body.
3. The pharmaceutical composition container described in claim 2 , wherein the aforementioned at least three spaces and the aforementioned cover are so arranged as to form one row, the aforementioned apertured space is positioned on one end of the aforementioned row, the aforementioned cover is positioned on the other end of the aforementioned row, the aforementioned container body and the aforementioned cover can be folded over, and folding over the aforementioned container body and the aforementioned cover brings the aforementioned aperture and the aforementioned cover into a state of facing each other.
4. The pharmaceutical composition container described in claim 1 , wherein an encapsulating item is stored in the aforementioned pharmaceutical composition chamber, at least the surface of the aforementioned encapsulating item melts in the ingredients of the aforementioned swallowing-aid substance, and the aforementioned encapsulating item contains the aforementioned pharmaceutical composition.
5. A pharmaceutical composition container equipped with a plurality of spaces in a container body, wherein the aforementioned container body is provided with a predetermined aperture part in which an aperture is to be formed, the aforementioned aperture opens when force is applied from the outside of the aforementioned pharmaceutical composition container, thereby interconnecting the outside of the aforementioned pharmaceutical composition container with the aforementioned spaces, the portions between two adjoining spaces are sealed, the aforementioned portions between two adjoining spaces open when force is applied from the outside of the aforementioned pharmaceutical composition container, a swallowing-aid substance is stored in a swallowing-aid substance chamber which is at least one of the aforementioned spaces, a pharmaceutical composition is stored in a pharmaceutical composition chamber which is at least one of the aforementioned spaces, the aforementioned container body can be folded over, the aforementioned pharmaceutical composition container is further equipped with a cover that is disposed so as to adjoin the aforementioned container body, is integrated with the aforementioned container body and can be inserted into and pulled out of the portion on the aforementioned container body where the aforementioned predetermined aperture part is provided, and the aforementioned portion where the predetermined aperture part is provided is covered by the aforementioned cover.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2009/055974 WO2010109612A1 (en) | 2009-03-25 | 2009-03-25 | Medical composition container |
JPPCT/JP2009/055974 | 2009-03-25 | ||
PCT/JP2010/055214 WO2010110368A1 (en) | 2009-03-25 | 2010-03-25 | Pharmaceutical composition container |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120006704A1 true US20120006704A1 (en) | 2012-01-12 |
Family
ID=42780321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/257,426 Abandoned US20120006704A1 (en) | 2009-03-25 | 2010-03-25 | Pharmaceutical composition container |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120006704A1 (en) |
EP (1) | EP2412358A4 (en) |
KR (1) | KR101723197B1 (en) |
CN (1) | CN102438574A (en) |
WO (2) | WO2010109612A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130054247A (en) * | 2010-03-29 | 2013-05-24 | 가부시키가이샤 모리모토이야쿠 | Container for orally ingested pharmaceutical composition |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1611119A (en) * | 1926-09-24 | 1926-12-14 | Lipper Mfg Co Inc | Textile-mounted camphor ball |
US3070094A (en) * | 1959-02-25 | 1962-12-25 | Stanley J Sarnoff | Medicament and diluent storing, mixing, and dispensing device |
US3478871A (en) * | 1968-04-29 | 1969-11-18 | Kleer Vu Ind Inc | Burst package with fold seal |
US4402402A (en) * | 1981-10-14 | 1983-09-06 | Pike Brian R | Barrier seal multiple-compartment package |
US4534509A (en) * | 1982-09-28 | 1985-08-13 | Firmenich Sa | Multiple compartment plastic packing |
US5207320A (en) * | 1989-05-24 | 1993-05-04 | Allen Nicholas J | Compartmented mixing device with bead |
US20070119862A1 (en) * | 2005-11-29 | 2007-05-31 | Backes Larry P | Unit dose flexible container |
US20080113019A1 (en) * | 2005-06-06 | 2008-05-15 | Ajinomoto Co., Inc. | Composition for capsule coating |
US8157783B2 (en) * | 2004-06-02 | 2012-04-17 | Hosokawa Yoko Co., Ltd. | Medical liquid container |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8306400L (en) * | 1983-01-24 | 1984-07-25 | Bard Inc C R | MIXING PACKAGING WITH A MULTIPLE TRAY |
IT8253314V0 (en) * | 1983-11-04 | 1982-05-21 | Farmigea Spa | SINGLE-DOSE OR MULTI-DOSE CONTAINERS IF OF PHARMACEUTICAL PRODUCTS |
JP2766517B2 (en) * | 1989-07-24 | 1998-06-18 | 株式会社ニッショー | A protector that seals and protects the blood access tube of the blood bag |
US5462526A (en) * | 1993-09-15 | 1995-10-31 | Mcgaw, Inc. | Flexible, sterile container and method of making and using same |
JPH10234820A (en) * | 1996-12-25 | 1998-09-08 | Takeda Chem Ind Ltd | Granular agent jointly using dense fluid substance and double chamber type container therefor |
JPH10291538A (en) * | 1997-04-17 | 1998-11-04 | Material Eng Tech Lab Inc | Drug container |
AUPP313398A0 (en) * | 1998-04-22 | 1998-05-14 | Boston Research And Development Company | Disposable fluid or particulate applicator |
SE9902610D0 (en) * | 1999-07-07 | 1999-07-07 | Astra Ab | Sealing device at medical container |
JP4189845B2 (en) * | 2002-02-12 | 2008-12-03 | ニプロ株式会社 | Multi-chamber container |
JP4656302B2 (en) * | 2005-03-25 | 2011-03-23 | 藤森工業株式会社 | Multi-chamber container |
-
2009
- 2009-03-25 WO PCT/JP2009/055974 patent/WO2010109612A1/en active Application Filing
-
2010
- 2010-03-25 EP EP10756164.9A patent/EP2412358A4/en not_active Withdrawn
- 2010-03-25 KR KR1020117024736A patent/KR101723197B1/en active IP Right Grant
- 2010-03-25 CN CN2010800119699A patent/CN102438574A/en active Pending
- 2010-03-25 US US13/257,426 patent/US20120006704A1/en not_active Abandoned
- 2010-03-25 WO PCT/JP2010/055214 patent/WO2010110368A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1611119A (en) * | 1926-09-24 | 1926-12-14 | Lipper Mfg Co Inc | Textile-mounted camphor ball |
US3070094A (en) * | 1959-02-25 | 1962-12-25 | Stanley J Sarnoff | Medicament and diluent storing, mixing, and dispensing device |
US3478871A (en) * | 1968-04-29 | 1969-11-18 | Kleer Vu Ind Inc | Burst package with fold seal |
US4402402A (en) * | 1981-10-14 | 1983-09-06 | Pike Brian R | Barrier seal multiple-compartment package |
US4534509A (en) * | 1982-09-28 | 1985-08-13 | Firmenich Sa | Multiple compartment plastic packing |
US5207320A (en) * | 1989-05-24 | 1993-05-04 | Allen Nicholas J | Compartmented mixing device with bead |
US8157783B2 (en) * | 2004-06-02 | 2012-04-17 | Hosokawa Yoko Co., Ltd. | Medical liquid container |
US20080113019A1 (en) * | 2005-06-06 | 2008-05-15 | Ajinomoto Co., Inc. | Composition for capsule coating |
US20070119862A1 (en) * | 2005-11-29 | 2007-05-31 | Backes Larry P | Unit dose flexible container |
Also Published As
Publication number | Publication date |
---|---|
KR20110131296A (en) | 2011-12-06 |
WO2010109612A1 (en) | 2010-09-30 |
CN102438574A (en) | 2012-05-02 |
EP2412358A1 (en) | 2012-02-01 |
KR101723197B1 (en) | 2017-04-05 |
EP2412358A4 (en) | 2014-10-29 |
WO2010110368A1 (en) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8720679B2 (en) | Container for orally ingested pharmaceutical composition | |
EP2702976B1 (en) | Container for administering medication | |
US9902508B2 (en) | Delivery device with separate chambers connectable in fluid communication when ready for use, and related method | |
US20120012480A1 (en) | Pharmaceutical composition container | |
US20120006704A1 (en) | Pharmaceutical composition container | |
JPWO2004100859A1 (en) | Container for swallowing solid molded product for oral consumption, container for container, and swallowing method | |
JP2011200261A (en) | Dosed article housing container | |
CN105722492B (en) | Packet body, method for producing packet body, and apparatus for producing packet body | |
JP5588967B2 (en) | Pharmaceutical composition container | |
JP5792939B2 (en) | Pharmaceutical composition container | |
WO2010110367A1 (en) | Medicinal composition container | |
US20200369454A1 (en) | Container and method for reconstitution of substances | |
JP4312428B2 (en) | Manufacturing method of multi-chamber package | |
WO2004099028A1 (en) | Flexible multichamber mixing container | |
JP5473629B2 (en) | Container for swallowing | |
WO2011122639A1 (en) | Container for orally ingested pharmaceutical composition | |
JP3732243B2 (en) | Pouch | |
JP5897145B2 (en) | Drug oral administration device | |
WO2016035134A1 (en) | Container for swallowing, container set for swallowing, method for manufacturing container set for swallowing, and device for manufacturing container set for swallowing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MORIMOTO-PHARMA CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORIMOTO, SHUJI;SAKUMA, YUTAKA;REEL/FRAME:026928/0657 Effective date: 20110909 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |